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Abstract 
The objectives of this thesis were; 1) to assess the effect of white matter hyperintensities 
(WMH) burden on motor outcomes among older individuals in the presence and absence of 
overt neurological conditions, and 2) to evaluate whether physical activity (PA) moderated 
the association between WMH and gait velocity and stride time variability (STV), under 
single and dual-task conditions, in a geriatric clinic sample. Study 1 systematically reviewed 
the literature demonstrating that greater WMH burden was associated with predefined motor 
outcomes. Notably, gait velocity emerged as a well-studied characteristic. Study 2 confirmed 
that WMH negatively affected gait velocity. STV and dual-task gait conditions did not reveal 
significance. Additionally, PA did not moderate the association between WMH and gait 
velocity, although conditional effects showed significance for low and moderate levels of 
PA. This finding extends support for the efficacy of physical activity in attenuating the 
effects of WMH on mobility. 
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Chapter 1  
1 Literature Review 
This thesis aims to evaluate the association between white matter hyperintensities and 
motor outcome, specifically quantitative gait characteristics, and whether this association 
is modified by physical activity among older individuals. Chapter 1 will introduce the 
topic of mobility in aging, focusing on the role of the central nervous system affecting 
mobility. A brief overview of gait performance in aging will be presented and the inter-
relationship with cognitive functions will be explored. In addition, this chapter will 
discuss the impact white matter hyperintensities detected on magnetic resonance imaging 
have on quantitative gait characteristics as well the neuroprotective effect of physical 
activity against cognitive and physical functioning decline in aging. We conclude by 
providing the study rationale, purpose and hypotheses of the subsequent chapters. 
1.1 Mobility in Aging 
Mobility is essential for humans as the capacity to move underlies many basic and 
community functions necessary for independence [1]. Mobility limitations defined as a 
restriction in an individual’s ability to move around the environment are common in 
aging, affecting approximately one-third to one-half of adults aged 65 years and older [1]. 
The consequences of mobility limitations represent a serious health and economic burden 
as they can render significant impact on overall physical functioning, ultimately leading 
to loss of independence, future falls, mobility disability and mortality [2-4]. Converging 
evidence suggests that gait performance is a clinical marker of mobility, in which specific 
quantitative characteristics (i.e., velocity and variability) are associated with future 
adverse outcomes in older adults [5-7]. During the last decade, mounting evidence has 
supported that the central nervous system plays a key role in regulating walking and gait 
performance, even in older adults without neurological diseases. Specifically, low 
cognitive functions in attention, executive function, and semantic memory are associated 
with mobility decline and future falls [8, 9]. Additionally, emerging evidence from 
neuroimaging studies support that gait performance and cognitive processes share similar 
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brain networks and regions [10-12]. Therefore, understanding the role of neurological 
markers in association with quantitative gait characteristics is important in preventing and 
treating mobility limitations along with potential disabilities.  
For the purpose of this chapter, our discussion in the following sections will focus solely 
on gait as a marker of mobility given the overwhelming evidence in support for this 
association. 
1.2 Gait 
Gait is a complex clinical entity defined as the pattern of movement of the body during 
locomotion, which enables humans to move forward [9, 13]. It has a multitude of 
determinants requiring the integration of the cardiopulmonary, musculoskeletal, nervous 
and sensory systems [6, 9, 14-18]. Accordingly, alterations to these systems necessary for 
facilitating gait functions may lead to the manifestation of gait disorders.  
The effects of aging on gait performance are commonly recognized. Furthermore, 
although gait alterations are demonstrated in older adults with specific neurological 
conditions, they are also reported in otherwise healthy older individuals [19-21]. Hence, 
studying gait processes beyond disease-based models is crucial for understanding and 
preventing the onset of clinical impairment. 
1.2.1 The Gait Cycle 
The gait cycle is used to describe the time from when the heel of one foot makes contact 
with the ground (heel strike) to the following heel strike of the same foot [22, 23]. The 
cycle is characterized in two phases: the stance phase and the swing phase (see Figure 
1.1). The stance phase represents approximately 60% of the gait cycle, starting and 
ending with both feet on the ground with one foot maintaining constant contact with the 
ground. This phase is divided into the initial heel strike, loading response, mid-stance, 
terminal stance and pre-swing. The remaining 40% of the gait cycle is referred to as the 
swing phase. The swing phase occurs simultaneously with the stance phase and 
represents the interval at which the opposing foot is not in contact with the ground. This 
phase is divided into toe-off, mid-swing, and terminal swing. 
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Figure 1.1 Phases of the normal gait cycle. Adapted from Pirker & Katzenschlager 
[18]. 
1.2.2 Classification of Gait Disorder in Older Adults 
As proposed by Nutt, Marsden and Thompson [24], gait disorders can be hierarchically 
divided into lower, middle and higher levels (see Table 1.1). Lower-level gait disorders 
refer to deficits in the lower extremity or peripheral dysfunction contributing to changes 
in gait. Middle-level gait disorders refer to disruptions in motor and sensory modulation 
of gait affecting the execution of gait while the initiation process remains preserved. 
Lastly, higher-level gait disorders refer to the deficits not explained by peripheral motor, 
sensory, pyramidal, cerebellar, or basal ganglia lesions. At this level, categorization of 
gait characteristics is non-specific, where altered cognitive and attention processes, and 
behavioral deficits may be present.  
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Table 1.1 Common cause of gait disorder in older people according to the hierarchic 
sensorimotor level 
 
Adapted with permission from Montero-Odasso M. “Falls as a Geriatric Syndrome: 
Mechanisms and Risk Identification”. Chapter in Osteoporosis in Older Persons: 
Advances in Pathophysiology and Therapeutic Approaches by Duque & Kiel [25]. 
1.2.3 Epidemiology of Gait Disorders 
The prevalence and incidence of gait disorders or impairment in older adults varies 
between studies as results of the quantification methods used, as well as the population of 
interest. However, studies including community-dwelling older adults have been 
relatively consistent. For example, the Bruneck Study, a population-based study of older 
individuals between 60–97 years of age, reported that the prevalence of impaired gait 
based on a comprehensive and standardized clinical examination using a three-step model 
for classification was 32.2% (95% confidence interval [CI] = 28.2–36.4) [26]. Similarly, 
the Einstein Aging Study, a prospective cohort study of older adults between 70–99 years 
of age, reported that the prevalence of gait disorder based on clinician observation and 
diagnosis was 35% (95% CI = 28.6–42.1) and the incidence of abnormal gait was 168.6 
per 1,000 person years (95% CI = 117.4–242.0) [27]. 
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In addition, both studies demonstrated that the prevalence of gait disorders increases with 
age [26, 27]. The Bruneck Study showed that the prevalence of gait disorders for older 
individuals 60–69 years of age was 10% (95% CI = 7.1–15.8) and increased to 61.7% 
(95% CI = 52.7–69.9) in those over 80 years of age [26]. The Einstein Study reported that 
the prevalence of abnormal gait in older adults 70–74 years of age was 24.3% (95% CI = 
16.4–34.5) increasing to 45.9% (95% CI = 26.5–66.7) in those 85 years of age and older 
[27]. The same study reported that the incidence of abnormal gait in those 70–74 years of 
age was 116.4 per 1,000 person years (95% CI = 62.3–217.5) and in those 85 years of age 
and older the incidence of abnormal gait was 502.8 per 1,000 person years (95% CI = 
284.5–888.6) [27].  
1.2.4 Methods of Gait Analysis   
Gait analysis refers to the data gathering process of an individual’s walk [23]. There are 
various methods of gait analysis including: observational gait analysis, timing of the gait 
cycle, direct motion measurement systems, and electrogoniometers among many others. 
The applications of gait analysis techniques are dependent on whether it is used for 
clinical or research purposes [23]. Clinical gait assessment aims to aid in the treatment of 
patients, whereas gait assessment for research aims to improve our understanding of gait 
[23]. 
1.2.4.1 Observational Methods of Gait Analysis  
Observational methods of gait analysis can include clinical examinations, or simple timed 
pencil-and-paper tests using a stop watch and a marked path on the ground. For clinical 
examinations, an individual is asked to complete a number of walks as an observer, 
usually a clinician, examines various characteristic of the walk. Parameters evaluated 
during the clinical examination of gait may include: gait initiation, velocity, turning, arm 
swing, posture, and many more [18, 23, 28]. On the other hand, simple timed tests 
typically involve measuring the velocity, number of steps, or cadence (steps per minute) 
of an individual’s walk over a pre-selected distance. Although both of these approaches 
demonstrate feasibility within clinical settings, the former is time consuming, relies on 
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clinician expertise, and can only detect clinically evident gait abnormalities. The latter 
provides a quantitative measure of gait, which is usually affected before clinically 
detectable gait impairments. 
1.2.4.2 Instrumented Methods of Gait Analysis 
Instrumented methods of gait analysis are highly sophisticated techniques with the 
capacity to provide precise gait parameters. Specifically, quantifiable spatial and 
temporal characteristics can be acquired through the use of computerized electronic 
walkway systems (see Table 1.2 and Figure 1.2). These electronic walkways are 
embedded with pressure sensors that are activated through foot contact (see Figure 1.3). 
Computerized walkways have gained much acceptance within research as they are 
feasible, with easy transportation and implementation across a wide-range of settings 
(e.g., clinic- or community-based). Additionally, they are a valid and reliable tool, 
providing a quick alternative to observational methods [29, 30]. Furthermore, 
characteristics of gait velocity and gait variability, which can be acquired through 
computerized walkways, have emerged as outcomes that may implicate subclinical 
impairment. 
Table 1.2 Definitions of quantitative gait characteristics 
Variable Units Definition 
Velocity  meters/second Distance covered by the time to ambulate  
Cadence steps/minute Number of steps by the time to ambulate 
Stride length meters Distance between heel points of two consecutive 
footfalls of the same foot. 
Step length meters Distance between the heel points of two consecutive 
footfalls of the opposite foot 
Step width meters Distance between the midpoint of the two 
consecutive footfalls of the opposite foot 
Stride time seconds Duration to ambulate one stride length 
Step time seconds  Duration to ambulate one step length 
Double support seconds Duration of when both limbs are in contact with the 
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time ground 
 
 
Figure 1.2 Basic terminology describing the gait cycle. Adapted from Pirker & 
Katzenschlager [18]. 
 
Figure 1.3 Schematic of GAITRite® electronic walkway. Adapted from CIR 
Systems, Inc. at http://www.gaitrite.com/WI-02-15_Technical_Reference_T.pdf. 
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1.2.5 Gait Velocity 
Gait velocity, which is the distance covered by the time to ambulate is a simple yet 
effective measure of mobility [31]. It can be attained both through the use of 
observational and instrumented methods of gait analysis, demonstrating feasibility within 
clinical practice. Moreover, gait velocity has demonstrated extensive predictive 
capabilities for a wide range of outcomes in older adults including limitations in activities 
of daily living, mobility disability, institutionalization, falls, mortality, and dementia [7, 
32-36]. In addition, the responsiveness of gait velocity, that is, the ability to detect real 
change over time across different settings and in various clinical populations, has led to 
the designation of this measure as the “6th vital sign” [36-38].  
1.2.6 Gait Variability  
Gait variability is an emerging quantitative gait parameter that has received considerable 
attention in recent years. Gait variability refers to the magnitude of the stride-to-stride 
fluctuations of gait characteristics during the gait cycle [13]. It is obtained by using either 
the standard deviation (SD) or the coefficient of variation (CoV; SD divided by the mean) 
of the gait characteristics of interest. Previously, stride-to-stride fluctuations were 
regarded as “noise” within the data and were dismissed as having little to no relation to 
the intrinsic mechanisms necessary for normal gait [39]. However, studies now support 
that the stride-to-stride fluctuations in gait measures (i.e., gait variability) are a clinically 
relevant feature of gait.  
A prospective cohort study of community-dwelling older adults found that increased 
stride time variability predicted falls [40]. In fact, there was a 5-fold increased risk for 
falls in older adults with higher stride time variability [40]. To visualize these effects, 
Figure 1.4 illustrates the stride-to-stride fluctuations in a faller and a non-faller during the 
12-month study follow-up. Moreover, other studies have demonstrated an association 
between measures of gait variability and mobility disability [5, 41], frailty [42], falls [35, 
43] and dementia [44, 45], further emphasizing the clinical utility in this measure. More 
importantly, several studies have indicated that gait variability may be a more sensitive 
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measure than gait velocity of assessing mobility impairment [35, 39, 46, 47]. Despite the 
sensitivity in gait variability to predict impairment, Beauchet and colleagues [48] 
suggests that gait velocity and gait variability should be explored concurrently, not 
separately. 
  
	
Figure 1.4 Stride time variability at baseline in a 78-year old man who experienced a 
fall during the 12-month follow up (SD = 66 ms), compared to an 84-year old man 
who did not fall (SD = 29 ms). Adapted with permission from Hausdorff, Rios and 
Edelberg [40]. 
1.3 Gait and Cognition  
Gait had been considered as an automatic motor task requiring minimal neural input. 
However, emerging evidence supports that gait performance relies on higher-level 
cognitive processes. Evidence for this association has been demonstrated indirectly in 
studies examining cognition. Although there are several definitions, we define cognition 
as “the intellectual or mental process whereby an organism becomes aware of or obtains 
knowledge” [49]. As such, it comprises a variety of functions including executive 
functions, attention, working memory, long-term memory, reasoning, decision making, 
problem-solving, speech and language, planning in addition to many others [50]. 
Noteworthy, similar to gait, cognitive functions generally worsen during the aging 
process and have also been demonstrated in individuals with and without overt 
neurological conditions.  
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Additionally, numerous studies suggest that clinical entities of gait impairment and 
cognitive impairment may coexist in older individuals. For example, the association 
between low cognition functions and poor gait performance have been demonstrated in 
general older adults samples and in individuals with mild cognitive impairment (MCI) 
and dementia [31, 51-53]. One study in particular even demonstrated that slowing gait 
speed precedes the development of clinically detectable cognitive changes (i.e., onset of 
MCI) in older adults [54]. Moreover, a recent systematic review and meta-analysis of 37 
prospective studies including older adults without overt neurological conditions reported 
that lower limb motor function was associated with higher risk of incident dementia 
(pooled hazard ratio [HR] = 1.94, 95% CI = 1.41–2.65) [32]. Hence, it is postulated that 
the co-occurrence of these two clinical entities may be a result of shared risk factors and 
underlying brain networks [55, 56].      
1.3.1 Executive Functions  
Executive functions refer to a series of mental processes that collectively produce and 
modulate goal-directed behaviours [57, 58]. This includes mental shifting, information 
updating and monitoring, and inhibition [57]. Not surprisingly, impairments to executive 
function subdomains impact an individual’s ability to walk safely. For example, walking 
in the real-world is a goal-directed action that involves continually attending, integrating, 
and responding to environmental perturbations to ensure stable movement. In fact, there 
is substantial evidence in the literature to support that poor performance on tests of 
executive functions are associated with gait performance [58-60]. While studies have 
demonstrated an association between general measures of executive functions, specific 
domains of executive functions (i.e., attention) have also been demonstrated in 
association with poor gait outcomes [58, 61].  
1.3.2 Attention 
Attention refers to a specific subdomain of executive functions whereby an organism 
perceives a stimulus and begins processing this incoming information [58]. There are 
different forms of attention including focused, sustained, divided and alternating. 
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Focused attention includes selecting a relevant stimulus while supressing irrelevant 
distractors [62]. Sustained attention refers to maintaining focus on a task over an 
extended period of time [63]. Divided attention is the ability to carry out more than one 
task simultaneously and alternating attention is the shifting of one task to the next [62]. 
Walking comprises varying types of attention demands, especially divided attention as 
walking in the real-world typically involves carrying out multiple tasks as once [58, 61]. 
Of particular interest, divided attention represents the basis for the dual-task paradigm, 
which posits that the attention demands of multi-tasking while walking has clinical 
implications for risk of falls.  
1.3.3 Dual-Task Paradigm 
In a seminal paper by Lundin-Olsson et al. [64], researchers demonstrated in a sample of 
nursing home residents that the inability to maintain a conversation while walking, or 
those who ‘stopped walking when talking’ were more likely to fall [64]. Since then, 
observing gait characteristics of an individual’s walk while performing a secondary 
attention demanding task has been used to evaluate the relationship between gait and 
cognition. The underlying hypothesis of the dual-task paradigm suggests that performing 
more than one task at once will interfere and compete for neural resources required for 
walking [58]. The resultant gait modifications are interpreted as increased “cost” of 
involvement of higher level cognitive processes while walking. As such, gait 
performance under dual-task conditions is dependent on an individual’s ability to 
adequately allocate the necessary resources for two simultaneously performed tasks. 
In general, dual-task performance may impact gait by decreasing velocity and increasing 
variability [13, 40]. In fact, several studies have provided evidence in support for this 
association. These studies suggest that the effects of dual-tasking on gait velocity and 
variability are much higher in individuals with cognitive impairment than in healthy 
controls [11, 65-67]. Furthermore, a recent prospective cohort study among 112 older 
individuals with MCI revealed that dual-task cost in gait velocity while counting 
backwards by one (HR = 3.42, 95% CI = 0.99–11.71, p = 0.05) and naming animals (HR 
= 2.41, 95% CI = 1.04–5.59, p = 0.003) was associated with progression to dementia 
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[68]. Interestingly, single-task gait velocity did not show significance [68]. The clinical 
relevance of dual-tasking is emphasized through its assumed simulation of real-life 
situations, where falls are more likely to occur, but also its ability to detect subtle brain 
deficits [69]. 
There are three main theories to explain the dual-task paradigm, in particular dual-task 
cost. The first is the capacity-sharing theory, which suggests attentional resources are of 
finite capacity such that presenting two or more stimuli within close succession of one 
another will result in deterioration in at least one task if performing both tasks shares 
capacity [70]. This theory has been applied to tasks that are over-learned and automatic 
(i.e., walking). The second theory is the bottleneck theory, which suggests that a delay or 
‘bottleneck’ is likely to occur if two tasks are processed by the same neural networks 
[71]. As a result, processing of the second task will occur after the neural networks are 
free from processing the first task. The last theory is the multiple resource model theory, 
which suggests that dual-tasking requires a number of resources and if two tasks are not 
from common resources, dual-task cost will not occur [58]. Alternatively, if the two task 
share the same resources (i.e., use the same neurons), they will also not disturb each other 
due to increased activation.      
1.3.4 Risk Factors for Gait and Cognitive Decline in Aging 
Previously, Pugh and Lipsitz [56] proposed the “Microvascular Frontal-Subcortical 
Syndrome of Aging” to help explain the “phenotypic” changes of the cognitive and motor 
systems. This model suggests that the clinical features of aging related to the frontal-
subcortical structures may result from age-related neuronal changes in addition to 
vascular damage resulting from the accumulation of cardiovascular risk factors [56]. 
Previous research shows robust evidence linking vascular risk factors to cognitive 
impairment, dementia and Alzheimer’s disease [72-78]. Similar results have also been 
demonstrated for the association between vascular risk factors and gait outcomes 
including slowing gait velocity and increased dual-task cost [75, 79-81].   
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While the relationship between gait and cognition is well-established, converging 
evidence from neuroimaging studies also supports this association. Specifically, gait and 
cognitive functions are governed by frontal-subcortical neural networks that are in close 
proximity to one another [55, 56]. These networks are located within watershed areas of 
cerebral perfusion that are vulnerable to the effects of vascular risk factors and 
subsequent formation of white matter hyperintensities (WMH) [55, 56, 82, 83]. Not 
surprisingly, WMH have been associated with vascular risk factors, cognitive 
functioning, dementia, and motor outcomes (i.e., slowing gait velocity, balance, and falls) 
[21, 84-92]. Recently, a more inclusive model including aging, neurodegeneration, 
vascular brain disease and other factors has been proposed to explain the potential 
mechanisms affecting the common brain structures and network that govern gait control 
and cognitive performance (see Figure 1.5). Taken together, interventions aimed at 
alleviating vascular risk factor burden may also aid in preventing or slowing of motor and 
cognitive decline, in addition to the formation of WMH, contributing to frontal-
subcortical dysfunction. 
 
Figure 1.5 Potential mechanism affecting the common brain structures and 
networks that regulate gait control and cognitive performance. Adapted from 
Montero-Odasso, M et al. [93]. 
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1.4 White Matter Hyperintensities  
White matter hyperintensities are a common neuroimaging finding among older 
individuals appearing as hyperintense areas on T2-weighted, proton density-weighted 
(PD) and fluid attenuated inversion recovery (FLAIR) magnetic resonance imaging 
(MRI) sequences [94]. Generally, WMH appear as ‘caps’ on the frontal and/ or occipital 
horns (Figure 1.6A) or as a thin ‘lining’ along the lateral ventricles (Figure 1.6B). Such 
WMH are referred to as periventricular WMH. Alternatively, WMH can appear within 
areas of the subcortical white matter, otherwise referred to as deep WMH (Figure 1.6C). 
With increasing severity or progression of WMH, periventricular WMH may extend into 
areas of subcortical white matter becoming confluent (Figure 1.6D). Even though these 
findings of high signal areas were once regarded as a part of the normal aging trajectory 
and clinically innocuous, numerous studies suggest that WMH are clinically relevant 
biomarkers and therefore should not be overlooked. 
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Figure 1.6 White matter hyperintensities on FLAIR MRI scans; A) caps, B) thin 
lining, C) deep WMH, and D) confluent deep WMH.   
1.4.1 Epidemiology of White Matter Hyperintensities 
As mentioned earlier, WMH are a frequent finding on MRI scans of older adults with and 
without overt neurological conditions. Two large population-based studies, the 
Cardiovascular Healthy Study and the Rotterdam Scan Study, which included 
participants of 60 years of age and older, reported a high prevalence of WMH of 95% and 
96%, respectively [95, 96]. Additionally, several studies have revealed that the 
prevalence of WMH increases with the number of vascular risk factors including 
hypertension, diabetes and history of smoking [97-100].  
Aside from investigating overall prevalence, the Rotterdam Scan Study also examined the 
progression of WMH. Using a semiquantitative visual rating scale (providing a total and 
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partial regional WMH scores), this study reported progression of WMH in 39% of 
individuals over a 3-year follow-up period [99]. Predictors of WMH progression included 
magnitude of baseline WMH severity, and vascular risk factors of blood pressure and 
current smoking status, although no significant associations were reported for atrial 
fibrillation, carotid atherosclerosis and homocysteine [99]. 
1.4.2 Pathogenesis of White Matter Hyperintensities 
The pathophysiology of WMH is heterogeneous, however, it is hypothesized that WMH 
are a result of ischemia and inflammation [101]. The ischaemic mechanism suggests that 
endothelial damage including loss of smooth muscle cells, lumen restriction, and vessel 
wall thickening leads to decreased cerebral blood flow and loss of auto-regulation and 
tissue ischemia [102-104]. Tissue ischemia is characterized as demyelination, loss of 
oligodendrocytes and axonal damage [102, 104, 105]. Alternatively, endothelial damage 
can lead to disruption in the brain blood barrier, which allows toxins into the brain 
causing tissue damage appearing as areas of hyperintensities on MRI [102, 106, 107].   
1.4.3 Assessment of White Matter Hyperintensities 
Although there is no established ‘gold standard’ for quantifying WMH, numerous 
methods are available that yield an accurate measure of WMH. Broadly, there are two 
methods of assessment: semiquantitative visual rating scales and quantitative automated 
segmentation approaches. 
1.4.3.1 Semiquantitative White Matter Hyperintensities 
Assessment  
Semiquantitative WMH assessment, which uses a visual rating scale that has significant 
correlation with quantitative volumetric WMH techniques, provides a fast and reliable 
way for quantifying WMH. Some scales also have the advantage of delineating regional 
WMH volume, although it must be employed by an experienced rater and is limited to 
cross-sectional use only [108]. Examples of commonly used visual rating scales include 
the Fazekas and Scheltens. The Fazekas scale rates WMH on a 0-3-point scale, 
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combining both periventricular (areas along the lateral ventricles) and subcortical areas 
[109]. On the other hand, the Scheltens scale yields a score ranging from 0-82-points 
delineating periventricular and subcortical WMH, in addition to WMH in the basal 
ganglia and infratentorial regions. [110].  
1.4.3.2 Quantitative White Matter Hyperintensities Assessment  
Quantitative WMH assessment, such as automated segmentation programs, are capable of 
providing quick and precise measurement of WMH volume, and often times require 
minimal human input. As a result, automated segmentation methods eliminate inter-rater 
bias and can be useful for detecting small volumetric changes longitudinally [111]. While 
semiquantitative and quantitative methods of analysis can measure visually appreciable 
WMH, quantitative approaches can also detect subtle structural changes to the white 
matter integrity derived from diffusion-tensor imaging (DTI) [112].   
1.4.4 Clinical Consequences of White Matter Hyperintensities 
White matter hyperintensities are increasingly recognized as important neuroimaging 
biomarkers, particularly in relation to gait and cognition. Gait and cognitive impairments, 
as previously discussed, are common in aging and can progress to severe stages, 
manifesting as dementia and falls [8]. Numerous studies including a large meta-analysis 
demonstrated that WMH are associated with cognitive decline within domains of 
executive functions and an increased risk of dementia [88, 113-115]. In addition, WMH 
are also associated with poorer physical functions, resulting in slowing gait, balance 
instability and falls [19, 20, 87, 115, 116]. Furthermore, strategies aimed at improving 
risk factors (e.g., hypertension, diabetes) may prove vital to alleviating these 
consequences of WMH burden. 
1.5 Physical Activity 
Physical activity is defined as an individual’s daily activity involving bodily movement 
and the use of skeletal muscles [117]. Physical exercise, is a sub-domain of physical 
activity that is planned, structured and repetitive movement aimed at improving physical 
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fitness [118]. Physical activity is an important modifiable lifestyle factor and when 
prescribed as physical exercise, it has the capacity to maintain and improve areas of an 
individual’s physical health. The known effects of physical activity have been 
demonstrated in health conditions of diabetes, osteoarthritic and cardiovascular diseases, 
through which the effects of these conditions are attenuated [119-121]. More importantly, 
physical activity has demonstrated a protective effect against cognitive and physical 
functioning decline, especially in older adulthood. 
1.5.1 Physical Activity and Cognition in Aging 
The benefits of physical activity in delaying or offsetting the trajectory of age-related 
cognitive decline have been long recognized. For example, Yaffe and colleagues in a 
sample of 5,925 cognitively-healthy community dwelling older women (aged ≥ 65) 
examined the association between physical activity and cognitive decline over 8 years 
[122]. Physical activity was measured as the number of city blocks walked (1 block ≈ 160 
meters) each day as a part of daily exercise or normal routine and cognitive decline was 
assessed using the Mini-Mental State Examination (MMSE) at baseline and 6 to 8 years 
later. The authors reported that compared to the lowest quartile, the odds of developing 
cognitive decline was 34% lower (OR = 0.66; 95% CI = 0.54–0.82) among women in the 
highest quartile of blocks walked at baseline after adjusting for relevant covariates [122]. 
The authors further concluded that the odds of developing cognitive decline was 13% 
lower (OR = 0.87; 95% confidence interval [CI] = 0.82–0.92) for every 10 blocks per day 
(~1.6 km [1 mile]) [122]. 
Similarly, the Nurses’ Health Study investigated the association of physical activity on 
cognitive decline in 18,766 women aged 70–81 years [123]. Physical activity was 
measured by asking the women to estimate the amount of time spent partaking in pre-
specified activity (e.g., running, walking, racquet sports, lap swimming, dancing etc.) and 
cognitive function tested domains of global cognition, category fluency, working memory 
and attention, and verbal memory. Results from this study showed that compared to 
women in the lowest quintile of physical activity, the risk for cognitive impairment was 
20% lower for women in the highest quintile of activity (OR = 0.80; 95% CI = 0.67–
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0.95) [123]. Additionally, less cognitive decline over 2 years was seen in women that 
were more active; women in the fourth and fifth quintile had 0.04 (adjusted mean 
difference = 0.04; 95% CI = 0.01–0.07) and 0.06 (adjusted mean difference = 0.06; 95% 
CI = 0.03–0.08) standard units higher for global cognition than those in the lowest 
quintile [123]. Furthermore, when analysis was restricted to only walking, a significant 
association for less cognitive decline was detected in those who walked at an easy pace 
for at least 1.5 hours per week when compared to women that walked <38 minutes per 
week [123]. It suggests that above a certain threshold, even minimal physical activity 
time (1.5 hours per week = 13 minutes per day) has a protective effect against cognitive 
decline. 
Other studies with more representative samples show consistent results with 
aforementioned studies. The Monongahela Valley Independent Elders Survey (MoVIES) 
study examined the association between levels of physical activity and subsequent 
cognitive decline in 1,681 community-dwelling older adults (aged ≥ 65) over 2 years 
[124]. Physical activity was a self-reported composite measure of type, frequency, and 
duration of level of exercise engagement and cognitive decline was measured using 
change in the MMSE. It was reported that the odds of engaging in high exercise 
frequency and duration (≥30 minutes of exercise, ≥3 times per week) was independently 
associated with a 61% lower (OR = 0.39; 95% CI = 0.19–0.78) risk of cognitive decline 
(≥3 MMSE points) when compared to no exercise [124]. 
Moreover, longitudinal studies have also examined the association between levels of 
physical activity and subsequent cognitive impairment and dementia For example, the 
Canadian Study of Health and Aging (CSHA) investigated the association between 
physical activity and occurrence of cognitive impairment and dementia in a sample of 
4,615 community-dwelling older adults over a 5-year follow-up [125]. Physical activity 
was a self-reported composite measure of frequency and intensity of an individual’s 
regular activity. Cognitive diagnoses (i.e., cognitive impairment-no dementia [CIND], 
Alzheimer’s disease [AD; probable or possible], vascular dementia, and unclassified 
dementia) were made by a clinician. It was reported that when compared to no physical 
activity, high levels of physical activity were independently associated with decreased 
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risk of CIND (OR = 0.58; 95% CI = 0.41–0.83), AD (OR = 0.50; 95% CI = 0.28–0.90) 
and any dementia (OR = 0.63; 95% CI = 0.40–0.98) [125].  
1.5.2 Physical Activity and Gait in Aging 
The protective benefits for physical activity and physical function has also been 
recognized among the elderly. For example, the Health, Aging and Body Composition 
(Health ABC) study examined the cross-sectional association between physical activity 
and physical function in 3,075 high-functioning older individuals aged 70–79 years 
[126]. Physical activity level was measured using standardized questionnaires from 
commonly-used physical activity questionnaires and measures of physical functions, 
which included a 400-meter walk, the Established Populations for the Epidemiologic 
Studies of the Elderly (EPESE) and the Health ABC battery. Results showed that after 
adjusting for relevant covariates, the active lifestyle group took significantly less to time 
complete the 400-meter walk [126]. 
The Rush Memory and Aging Project investigated the association between physical 
activity and rate of mobility change in a sample of 886 older adults without dementia 
[127]. Physical activity was measured using the National Health Interview Survey that 
yields a value of hours of activity per week and mobility was evaluated as the time and 
number of steps to walk 8-feet. The findings from this study suggested that higher levels 
of physical activity were associated with a slower rate of mobility decline [127]. Further 
interpretations suggested that each 1-hour increase of physical activity was associated 
with approximately 3% decrease in the rate of mobility decline [127].    
Mobility decline was also an outcome of interest in the Longitudinal Aging Study 
Amsterdam (LASA), a 3-year prospective study of 2,109 adults aged 55 to 85 years 
[128]. Physical activity was measured using self-reported questionnaires of an 
individual’s activity including sport participation and total activity time within the last 2 
weeks. Mobility performance was assessed using a timed walking test and a chair stand 
test. It was revealed that higher levels of baseline physical activity were associated with 
smaller change in mobility performance at 3-year follow up [128]. Additionally, change 
in physical activity was associated with change in mobility performance such that 
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individuals reporting stable activity during follow up, experienced smaller decline in 
performance [128].   
1.5.3 Physical Activity and White Matter Hyperintensities  
In comparison to the large body of studies examining the effects of physical activity on 
cognition and gait, far fewer studies have examined the relationship between physical 
activity and WMH. As a result, the association between physical activity and WMH is 
less well-established. The Northern Manhattan Study (NOMAS), a population-based 
study in 1,226 stroke-free older individuals assessed the association between physical 
activity and WMH volume [129]. Physical activity was measured using a self-reported 
questionnaire of an individual’s duration and frequency of leisure time and recreational 
activities for the past two weeks at baseline. Neuroimaging data acquisition occurred 6 (± 
3) years after the physical activity assessment, and WMH volume was measured using a 
semi-automated quantitative approach corrected for total intracranial volume, and log-
transformed to achieve normal distribution. No significant association between physical 
activity and WMH volume was detected [129].   
Another study, the Lothian Birth Cohort 1936 (LBC1936), examined the association 
between physical activity and WMH burden and the integrity of the normal-appearing 
white matter (NAWM; areas not including WMH) in 691 older adults [130]. Physical 
activity was measured using a 6-point self-reported questionnaire with items ranging 
from household chores to exercise and competitive sport. WMH was measured using 
both the semiquantitative Fazekas scale and semi-automated quantitative volumetric 
approach accounting for intracranial volume. The results of this study show that higher 
levels of physical activity independently predicted larger NAWM volume and lower 
WMH burden (volume and grade) [130]. In the final model, after adjusting for social 
class and disease, only WMH volume remained significant [130].   
The conflicting findings from these studies may be a result of the different physical 
activity measure employed in addition to the WMH methods of assessment. 
Alternatively, explanations to elucidate the benefits demonstrated in the previous sections 
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of cognition and gait may highlight the role of physiological mechanism of physical 
activity.  
1.5.4 Physiological Mechanisms Underlying Physical Activity Benefits  
The mechanisms underlying physical activity benefits are postulated to occur through 
central mechanism as well as through the reduction of peripheral risk factors. The central 
mechanism are facilitated through neurotropic factors, which promotes neurogenesis, 
central nervous system metabolism and angiogenesis [131-133]. In this regard, physical 
activity influences the growth, differentiation and maintenance of neurons across the 
lifespan by up regulating these neurotropic factors. Specific neurotrophins that have been 
demonstrated in this association include: brain-derived neurotropic factor (BDNF), 
insulin-like growth factor-1 (IGF-1) and vascular endothelial-derived growth factor 
(VEGF) [131]. 
Neurogenesis refers to the production of new neurons in brain regions important for 
memory, learning and overall performance [134]. Research of animal models has 
demonstrated that BDNF, which is synthesized and secreted by endothelial cells, is a key 
mediator for structural and functional plasticity [135, 136]. To support exercise-induced 
brain plasticity, there is an increase in metabolic demands that subsequently influences 
angiogenesis, the formation of new blood vessels [131, 137]. More specifically, it is 
believed that angiogenesis occurs through up regulation of IGF-1 and VEGF on 
endothelial cell proliferation and vessel growth [131]. 
In addition, physical activity reduces peripheral risk factors such as; hypertension, 
hyperglycemia and dyslipidemia [131]. These cardiovascular risk factors denoted as the 
‘metabolic syndrome’ have been previously discussed in the “Microvascular Frontal-
Subcortical Syndrome of Aging” explaining the phenotypic changes of the cognitive and 
motor systems [56, 138]. Further, inflammation is a common feature of these conditions 
and it is also shared in the pathophysiology of WMH [138, 139]. Interestingly, physical 
activity has been shown to greatly reduce peripheral risk factors and improve overall 
cardiovascular health [131]. Thus, physical activity represents a modifiable lifestyle 
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factor with the protective benefits to influence both central mechanism and peripheral 
risk factors subsequently attenuating the effect of WMH on gait characteristics. 
1.6 Overview of Thesis 
1.6.1 Study Rationale 
The previous section outlines the growing interest in mobility, particularly gait as an 
early marker of impairment and the role of neurovascular changes in the mobility decline 
seen in aging. Converging evidence suggests that WMH, an index of vascular burden, are 
associated with gait decline among older adults [84, 91]. Taken together, modifiable 
lifestyle strategies such as physical activity, previously demonstrated to improve vascular 
risk factors burden, may also ameliorate the effect of WMH on gait.  
1.6.2 Purpose 
The purpose of this thesis was; 1) to systematically review the association between WMH 
burden and motor outcomes of gait, balance, falls and fractures among older adults from 
general (absence of neurological disease) and clinical (neurological condition) samples 
and, 2) to determine whether the association between WMH and gait velocity and stride 
time variability, under single and dual-task condition, is moderated by physical activity. 
1.6.3 Hypotheses  
It was hypothesized that; 1) higher WMH burden will be associated with poor gait and 
balance performance and greater incidence and occurrence of falls and fractures, and 2) 
the association between WMH and gait characteristics under single and dual-task 
conditions will be moderated by physical activity, such that higher levels of physical 
activity will attenuate the effect of WMH on gait. 
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Chapter 2  
2 White Matter Abnormalities and Motor Outcomes: A 
Systematic Review and Meta-Analysis 
Brain white matter abnormalities, including white matter hyperintensities (WMH) are a 
common neuroimaging finding among older individuals [140, 141]. Converging evidence 
from previous studies suggests that motor performance and adverse motor outcomes 
including falls and fractures are associated with WMH burden; however, the magnitude 
of association is less well-established [20, 142, 143]. Noteworthy, because these poor 
motor outcomes result in serious health and economic burden, identifying the role of 
WMH burden may point to potentially modifiable factors to reduce falls, mobility 
disability, and mortality [9, 33, 34, 36, 144, 145].  
With the advent of contemporary neuroimaging techniques, studies have demonstrated 
widespread microstructural alterations in the areas of the normal-appearing white matter 
(NAWM) that surround these WMH [146]. Specifically, these alterations to the white 
matter integrity (WMI) quantified using diffusion tensor imaging (DTI) precede the 
development of WMH and reflect the magnitude of WMH burden [112, 146, 147]. 
However, the role of WMI in motor outcomes is unknown; and thus, given the continuum 
of white matter pathology, WMI may be an early marker of future decline in motor 
outcomes. 
Previous systematic reviews have focused solely on WMH, or on a single motor domain, 
and failed to establish the magnitude of association [84, 91]. Therefore, we conducted a 
comprehensive systematic review and meta-analysis to assess the associations between 
white matter abnormalities, both WMH and WMI, and motor outcomes among older 
adults from general and clinical samples. We included motor performance outcomes of 
gait, balance, and composite measures, in addition to adverse motor outcomes of falls and 
fractures.  
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2.1 Methods 
2.1.1 Search Strategy 
A comprehensive literature search, without date or language restriction, was conducted 
using EMBASE, MedLine, and PubMed. The search strategy combined medical subject 
headings (MeSH) and keywords related to ‘white matter abnormalities, ‘mobility’, and 
‘older adults’. Predefined search terms, syntax, and records yielded are described in 
Appendix A. Additional records were identified through backwards citation searching 
from included articles.  
2.1.2 Study Eligibility  
Studies were included if they met the following criteria: (1) published as an original study 
examining relationship between white matter changes and motor performance and 
mobility outcomes of interest, pre-specified below; (2) included a general (absence of 
neurological disease) or clinical (neurological condition) sample with mean age ≥60; (3) 
measured white matter changes using either structural MRI (T2-weighted or fluid 
attenuated inversion recovery [FLAIR]) for WMH or DTI for WMI; and (4) required that 
assessment and quantification of both white matter changes and motor performance and 
mobility outcomes were explicitly detailed in methods and/or referenced for validity. 
Studies using computed tomography were excluded due to lack of sensitivity [148]. 
All articles identified through database and hand searching were imported into EndNote 
[149]. Duplicate records were removed and the remaining articles were screened at three 
levels. One member of the team (NRL) screened the title of remaining articles to identify 
potentially relevant studies. Two reviewers (NRL and MMO) then independently 
assessed the abstracts of the articles identified from title screening. The remaining articles 
were then retrieved and screened on a full-text basis. Any disagreements were resolved 
by consensus.  
For studies with multiple publications, we included articles reporting the most detailed or 
relevant analysis of variables with the largest dataset. Additionally, articles containing the 
same study population were included if they presented a different white matter 
37 
 
quantification method, motor outcomes or if they used different sub-samples.  This 
criterion was applied to 6 publications [20, 142, 143, 150-152]. In cases where both 
cross-sectional and longitudinal data were presented from prospective cohort studies, we 
included that study in both cross-sectional and longitudinal analyses. The same procedure 
applied to studies presenting data for both WMH and WMI. Three studies were cross-
referenced; 2 studies [153, 154] reported both cross-sectional and longitudinal data, 
whereas one study reported data on both WMH and WMI [155]. 
2.1.3 Outcomes Measures  
The outcome measures of interest were grouped into four categories: motor-gait related, 
motor-balance related, motor-composite, and adverse motor outcomes. Motor-gait related 
outcomes included gait velocity and quantitative gait variables. Motor-balance related 
outcomes included postural sway and single-leg stand time (SLST). Motor-composite 
outcomes included Short Physical Performance Battery (SPPB), Timed Up and Go 
(TUG) Test and Tinetti Performance Oriented Mobility Assessment (POMA). Adverse 
motor outcomes included falls and fractures, modelled as history of falls and fractures for 
cross-sectional studies and as falls and fracture incidence for longitudinal studies. All of 
these measures have previously been associated, separately, with WMH [84, 91]. 
2.1.4 Data Extraction  
From eligible full-text articles we extracted first author, year of publication, country, 
study design, sample characteristics, sample size at baseline and follow-up, inclusion and 
exclusion criteria, type of measurement methods of white matter changes and motor 
performance test, and adverse motor outcomes of interest. We also extracted hazard 
ratios, odds ratios (OR), relative risk, correlation coefficients (Pearson’s and Spearman), 
and regression slopes when available to evaluate the strength of the association.  
2.1.5 Methodological Quality Assessment 
The methodological quality was assessed using the Downs and Black Checklist [156], 
modified for observational studies [157, 158]. High methodological quality was met 
when >50% of relevant items on checklist were present [158].  
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2.1.6 Meta-Analysis 
We conducted a random-effects meta-analysis and calculated the weighted mean effect 
size to determine the magnitude of association between total WMH and gait velocity in 
individuals in absence of overt neurological conditions. Computation of the weighted 
mean was based on Pearson’s product-moment correlation coefficient r as the effect size. 
Sensitivity analysis was further conducted by sequentially excluding studies quantifying 
WMH through semi-quantitative methods.  
We used the I2 statistic as a descriptive measure of variability to denote the proportion of 
true heterogeneity. This implies that larger proportions of variances (i.e. larger I2 values) 
would reflect more heterogeneity. No Egger test analysis using funnel plot asymmetry 
was conducted as there were fewer than 10 studies. All analyses were conducted using 
Comprehensive Meta-Analysis software [159]. 
2.2 Results 
2.2.1 Study Selection 
The initial search yielded 1,336 articles. After duplicate removal, 855 records were then 
screened for eligibility and 769 were excluded based on title and abstract. We retrieved 
and assessed 85 full-text articles, leaving 46 that met inclusion criteria (see Figure 2.1). 
To facilitate synthesis of data, we separated the studies method of white matter 
quantifications, either WMH (Table 2.1 and 2.2) or WMI (Table 2.3). Studies examining 
WMI were classified based on whether they performed whole brain (voxel-based analysis 
[VBA] or tract-based spatial statistics [TBSS]), or local analyses (region-of-interest 
[ROI] or tractography).  
39 
 
 
Figure 2.1 Flow diagram of study selection.
40 
 
Table 2.1 Characteristics of cross-sectional studies examining white matter hyperintensities and motor outcomes	
      WMH Motor Performance Outcomes Adverse Outcome 
Publication Study Country   N Age (years) Males (%) Measure Gait Balance Composite  Falls OR Fractures 
Ref. [19] LADIS Europe (multi-country) 639 43.7>75 45.1 Vis X Xa Xc − 
Ref. [160] LADIS Europe (multi-country) 639 74.1 45.1 Vis‡ − Xa − X f  
Ref. [161] − USA 54 81.6 44.4 Vis − − Xe − 
Ref. [155]* NAME  USA 173 72.8 25.4 Vol − − Xe − 
Ref. [85] Health ABC USA 253 82.7 42 Vol‡ X − − − 
Ref. [87] RUN DMC The Netherlands 431 63.8 54.8 Vol‡ X − Xd,e − 
Ref. [162] − Germany 34 69.4 32.4 Vis‡ X Xa Xc − 
Ref. [163] Sefuri  Japan 201 67.8 45.8 Vis‡ − − Xd† − 
Ref. [164] ** USA 99 83 42.4 Vol‡ − − Xc − 
Ref. [165] ** USA 99 82.1 40 Vol‡ X − Xc,e − 
Ref. [166] − USA 148 79 43.9 Vol‡ X − − − 
Ref. [167] − USA 76 64.7 47.4 Vol‡ X Xb − − 
Ref. [21] CHS USA 321 78.3 39.3 Vis‡ X − − − 
Ref. [168] CHS USA 331 78.3 NR Vis X − − − 
Ref. [169] AGES-RS Iceland 795 75.6 41.1 Vis X − − − 
Ref. [170] − Australia 81 76 46.9 Vis − − − Xg 
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Ref. [171] MBS USA 42 78.8 45.2 Vol X − − − 
Ref. [153]* 3C France 1702 72.4 39.4 Vol‡ X − − − 
Ref. [172] J-SHIPP Japan 1387 67 39.4 Vis‡ − Xb − − 
Clinical populations 
Ref. [173] − Canada 79 69.6 53.2 Vis X − − − 
Ref. [174] − Japan 560 72.9 53.6 Vis − Xb† − − 
Ref. [154]* − Japan 104 74.6 27.9 Vis‡ − Xb  − − 
Ref. [90] Sunnybrook Canada 44 73.6 45.5 Vis X† − − − 
Ref. [175] − Japan 163 77.3 30.7 Vis‡ − Xa,b Xd X f 
*=cross-referenced publications; **=same study cohort; N=sample size; NR=not reported; Vis=visual; Vol=volume; ‡= identified region of interests. 
3C, Three-City Study; AGES-RS, Age Gene/ Environment Susceptibility- Reykjavik Study; CHS, Cardiovascular Health Study; Health ABC, Healthy Aging and Body 
Composition Study; J-SHIPP, Japan Shimanami Health Promoting Program; LADIS, LeukoAraiosis And DISability Study; MBS, Mobilize Boston Study; NAME, Nutrition, 
Aging, and Memory in Elders Study; RUN DMC, Radboud University Nijmegan Diffusion Tensor Cohort Study; Sefuri, Sefuri Brain MRI Study; Sunnybrook, Sunnybrook 
Dementia Study. 
a=single-leg stance time; b=balance/postural sway; c=Short Physical Performance Battery; d=Timed-Up-And-Go; e=Tinetti Performance Oriented Mobility Assessment; f=falls; 
g=fracture; †=dual-task. 
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Table 2.2 Characteristics of longitudinal studies examining white matter hyperintensities and motor outcomes 
      WMH Motor Performance Outcomes Adverse Outcomes 
Publication Study Country   N Age (years) % Males  Measure Gait Balance Composite  Falls OR Fractures 
Ref. [176] **1 USA 59 78.5 57.6 Vol/ Vis − − − Xc 
Ref. [177] **1 USA 70 79 NR Vol§ − − Xb − 
Ref. [178] LADIS Europe (multi-country) 639 74.1 45.1 Vis − − Xa − 
Ref. [179] TASCOG Australia  225 71.4 56.4 Vol§ X − − − 
Ref. [180] TASCOG Australia 187 70.5 51.9 Vol§ − − − Xc 
Ref. [181] TASCOG/ MAS Australia  655 74.5 51.3 Vol − − − Xc 
Ref. [164] **2 USA 77 82 40 Vol§ X − − − 
Ref. [182] **2 USA 67 81.7 39 Vol§ X − Xa − 
Ref. [116] CHS USA 2450 74.4 43 Vis X − − − 
Ref. [183] OBA USA 104 85.1 38.5 Vol§‡ X − − − 
Ref. [153]* 3C France 1702 72.4 39.4 Vol‡ X − − − 
Ref. [184] WHICAP USA 701 80.3 32.8 Vol‡ X − − − 
Clinical populations 
Ref. [154]* − Japan 104 74.6 27.9 Vis‡ − − − Xc 
Ref. [185] SAM Finland 383 71 48.6 Vis − − − Xd 
*=cross-referenced publications; **(1,2)=same study cohort; §=progression of WMH; N=sample size; NR=not reported; Vis=visual; Vol=volume; ‡=identified region of interests.  
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3C, Three-City Study; CHS, Cardiovascular Health Study; LADIS, Leukoaraiosis And DISability Study; TASCOG, TAsmanian Study of COgnition and Gait; MAS, Sydney 
Memory Aging Study; OBA, Oregon Brain Aging Study; SAM, Stroke Aging Memory Cohort; WHICAP, Washington Hei ghts Inwood Columbia Aging Project.  
a=Short Physical Performance Battery; b= Tinetti Performance Oriented Mobility Assessment; c=fall; d=fracture.  
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Table 2.3 Characteristics of cross-sectional studies examining white matter integrity and motor outcomes 
      WMI Motor Performance Outcomes Adverse Outcomes 
Publication Study Country   N Age 
(years) 
Males 
(%) 
Measure Gait Balance Composite  Falls OR 
Fractures 
Ref. [155]* NAME USA 173 72.8 25.4 ROI‡ − − Xd − 
Ref. [186] ** Belgium 25 70.9 60 TBSS‡ X  Xa − − 
Ref. [187] ** Belgium 36 68.6 50 TBSS‡ − Xa − − 
Ref. [188]  Health ABC USA 16 74.6 62.5 ROI‡ X − − − 
Ref. [189] − USA 85 83 44.7 TBSS‡ X − Xb − 
Ref. [190] RUN DMC The Netherlands 429 65.2 54.8 TBSS/ROI‡ X − − − 
Ref. [191] RUN DMC The Netherlands 484 65.6 56.6 VBA/ROI‡ X − Xc,d − 
Clinical populations 
Ref. [192] − Singapore 65 72.4 78.5 Tractography‡ − − Xd − 
Ref. [193] − USA 30 73.2 63.3 Tractography‡ X − − − 
Ref. [194] − Japan 60 74.7 53.3 VBA − − Xc − 
Ref. [195] − Japan 38 71.1 NR ROI‡ − − Xc − 
*=cross-referenced publications; **= same study cohort; N= sample size; NR=not reported; ‡=identified region of interests. 
Health ABC, Healthy Aging and Body Composition Study; NAME, Nutrition, Aging, and Memory in Elders Study; Rotterdam, Rotterdam Study; RUN DMC, Radboud University 
Nijmegan Diffusion Tensor Cohort Study; ROI, region of interest; TBSS, tract-based spatial statistics; VBA, voxel-based analysis. 
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a=balance/postural sway; b=Short Physical Performance Battery; c=Timed-Up-And-Go; d= Tinetti Performance Oriented Mobility Assessment
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2.2.2 Study Characteristics 
The 46 publications retained for inclusion were all observational in design representing 
data collected from 32 unique study populations. Sample size ranged from 16 to 2,450, 
mean age ranged from 63.8 to 85.1 years, and proportion of men ranged from 25.4% to 
78.5%. Studies were geographically from Western Europe, North America, Japan, 
Singapore, and Australia. Clinical samples included Alzheimer’s disease (AD), Mild 
Cognitive Impairment, Frontal-Gait Disorder, Idiopathic Normal Pressure 
Hydrocephalus, Parkinson’s Disease (PD) and Ischemic Stroke.  
2.2.3 White Matter Hyperintensities and Motor-Gait Related 
Outcomes 
2.2.3.1 Cross-sectional Association 
Ten studies (n = 4,464) revealed statistically significant associations between greater 
WMH burden and slower gait velocity [19, 21, 85, 87, 153, 162, 165, 166, 169, 171]. The 
reported linear regression coefficients ranged from –0.017 to–0.14, and OR ranged from 
1.72 to 6.4. Values denoting impaired or abnormal gait velocity ranged from <1.2 to 
<0.67 meters/second. In contrast, one study including community-dwellers (n = 76) failed 
to find significant associations [167]. Sample size was a concern for this study.  
Studies assessing WMH and quantitative gait characteristics show mixed results. A 
population-based study reported in two publications (Cardiovascular Health Study; n = 
321 [21] and n = 331 [168]) found significant associations for double-support time and 
stride length variability but failed to find associations for stride length, stance time 
variability or step width variability [21, 168]. Conversely, two studies (n = 579) reported 
significant associations for stride length [87, 166]. Additionally, one of these studies (n = 
431) reported significant findings for stride width but not for double-support time, stride 
length variability, stride time variability or stride width variability [87].     
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One study examining dual-task cost on cadence, reported a significant decrease in 
performance in individuals with Alzheimer’s disease and higher WMH when compared 
to individuals with lower WMH [90]. 
2.2.3.1.1 Meta-Analysis  
The correlation coefficients of 5 studies examining total WMH on gait velocity yielded a 
highly significant overall effect of r = -0.29 (95% CI -0.40, -0.16; p < 0.01). Sensitivity 
analysis revealed that omitting studies on the basis of WMH quantification, either semi-
quantitative or quantitative, did not have an effect on association. See Figures 2.2 and 
2.3. 
 
Figure 2.2 Forest plot for association between white matter hyperintensities and gait 
velocity. 
Study name Statistics for each study Correlation and 95% CI
Lower Upper 
Correlation limit limit Z-Value p-Value
Ref. [32] -0.409 -0.663 -0.070 -2.339 0.019
Ref. [50] -0.290 -0.461 -0.098 -2.925 0.003
Ref. [33] -0.440 -0.561 -0.300 -5.686 0.000
Ref. [38] -0.200 -0.407 0.027 -1.732 0.083
Ref. [34] -0.180 -0.284 -0.072 -3.245 0.001
-0.293 -0.408 -0.168 -4.485 0.000
-1.00 -0.50 0.00 0.50 1.00
Slow Gait Velocity Fast Gait Velocity
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Figure 2.3 Forest plot of sensitivity analysis for association between white matter 
hyperintensities and gait velocity.  
 
  
Study name Statistics for each study Correlation and 95% CI
Lower Upper 
Correlation limit limit Z-Value p-Value
Ref. [50] -0.290 -0.461 -0.098 -2.925 0.003
Ref. [33] -0.440 -0.561 -0.300 -5.686 0.000
Ref. [38] -0.200 -0.407 0.027 -1.732 0.083
-0.342 -0.436 -0.241 -6.317 0.000
-1.00 -0.50 0.00 0.50 1.00
Slow Gait Velocity Fast Gait Velocity
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2.2.3.2 Longitudinal Association  
Four studies included community-dwelling older adults demonstrated significant 
associations between greater magnitude of baseline WMH and change in gait velocity (n 
= 2,450, follow-up = 4 years [116], n = 1,702, follow-up =  8 years [153], n = 67, follow-
up = 4 years [182], and n = 104, follow-up = 9.1 years [183]). In contrast, a population-
based study did not find significant results for transition from normal to abnormal gait 
velocity (n = 701, follow-up = 4.7 years) [184]. Moreover, two studies showed that the 
progression of WMH volume was associated with change in gait velocity (n = 225, 
follow-up = 2.5 years [179] and n = 77, follow-up = 4 years [182]). 
Aside from gait velocity, a population-based study (Tasmanian Study of Cognition and 
Gait; n = 225, follow-up = 30.6 months) revealed that WMH progression was associated 
with change in step length but not step width [179]. 
2.2.4 White Matter Hyperintensities and Motor-Balance Related 
Outcomes 
2.2.4.1 Cross-sectional Association  
Three studies from four publications (n = 836) quantified balance outcomes using the 
SLST test. Two studies (n = 673) reported significant associations for higher WMH 
burden and shorter stance times [19, 162]. In particular, a prospective cohort study 
(Leukoaraiosis and Disability Study [LADIS]; n = 639) in community-dwelling older 
adults reported that when compared to mild WMH, severe WMH was independently 
associated with increased risk of SLST <15 seconds (OR = 2.05; 95% CI = 1.30–3.25) 
[19]. The remaining two studies showed significant associations for regional WMH 
burden and shorter SLST test [160, 175]. 
Five studies (n = 2,290) quantified balance outcomes using measures of postural sway 
[154, 167, 172, 174, 175]. Significant associations for greater WMH burden and 
increased postural sway (decreased postural stability) were found in a MCI sample (n= 
560 [174]) and in a study of community-dwelling older adults (n= 1,387 [172]). The 
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remaining three studies identified significant regional WMH burden in association for 
decreased postural sway [154, 167, 175]. 
2.2.5 White Matter Hyperintensities and Motor-Composite 
Outcomes 
2.2.5.1 Cross-sectional Association  
Three studies from 4 publications (n = 772) examined WMH on SPPB outcomes [19, 
162, 164, 165]. Significant associations were found in two studies (n = 738) of 
community-dwelling older adults [19, 165]. The reported OR ranged from 1.75 to 2.29 
after adjusting for relevant covariates. In contrast, a study comprised a healthy older adult 
sample (n = 34) found no association for greater WMH burden and SPPB score [162]. 
Sample size may have contributed to lack of significant findings. The remaining study 
examined regional WMH burden and SPPB outcomes [164]. 
Three studies (n = 795) investigated WMH on TUG scores [87, 163, 175]. A prospective 
cohort study (Radboud University Nijmegen Diffusion Tensor and MRI Cohort Study 
[RUN-DMC]; n = 431) detected that those with severe WMH volume (i.e., fifth quintile 
[20.6–139.7 mL]) were four times more likely to have an abnormal TUG score >12 after 
adjusting for relevant covariates (OR = 4.4; 95% CI = 1.2-15.8) [87]. No association was 
found for TUG number of steps [87]. The other two studies found regional WMH 
correlated with longer TUG time [163, 175]. Anther study, examining dual-tasking using 
the TUG did not report significant associations for higher WMH and TUG under dual-
task condition, however, regional areas were identified in association for TUG (single-
task) alone [163].   
Four studies (n = 757) looked at WMH on total Tinetti scores [87, 155, 161, 165]. 
Significant associations between higher WMH and lower Tinetti scores were reported in 
three  studies (n = 326) of community-dwelling older individuals [155, 161, 165]. A 
prospective cohort study reported that for each 1% increase in WMH, individuals were 
almost two times more likely to have a Tinetti score ≤24 (OR = 1.98; 95% CI = 1.17–
3.38) [165]. Significant association was not found in a previously mentioned prospective 
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cohort study for Tinetti scores after adjusting for lacunar infarcts (RUN-DMC; n = 431) 
[87].  
2.2.5.2 Longitudinal Association  
Two studies (n = 706) examined WMH and motor-composite SPPB outcomes [178, 182]. 
Significant association was found in a study of community-dwelling older individuals 
between greater WMH burden at baseline and decline in SPPB score (LADIS; n = 639, 
follow-up = 3 years) [178]. In contrast, another study of community-dwelling older 
individuals failed to find statistically significant associations with baseline WMH and 
WMH progression and change in SPPB score (n = 67, follow-up = 4 years) [182].  
One study evaluating WMH and motor-composite Tinetti outcomes reported that the 
progression of WMH volume was significantly associated with >4 point change on the 
Tinetti score (n = 70, follow-up = 4 years) [177]. 
2.2.6 White Matter Hyperintensities and Adverse Motor Outcomes 
2.2.6.1 Cross-sectional Association  
Two studies (n = 802) examined WMH and falls, retrospectively [160, 175]. Significant 
associations were reported for higher regional WMH burden and falls from the year prior 
[160, 175].  
One study investigating adverse events of fractures found WMH to be significantly 
higher in those with traumatic hip-fractures compared with age-matched controls (n = 81) 
[170]. Regional correlates of WMH differentiating groups were also identified.  
2.2.6.2 Longitudinal Associations  
Four studies evaluated WMH and fall incidence [154, 176, 180, 181]. Two population-
based studies reported in one publication revealed significant association for greater 
magnitude of baseline WMH and falls (n = 655, follow-up = 1 year) [181]. Furthermore, 
in one of the aforementioned population-based study a significant associations was 
detected for WMH progression and greater risk for multiple falls after controlling for 
52 
 
 
relevant covariates (n = 187, follow-up = 2.5 years [180]). Contrary to the previous 
studies, one failed to report significant association (n = 54, follow-up = range 8-10 years) 
[176]. The remaining study examined baseline regional WMH and falls during a one year 
follow-up period [154]. 
An ischemic stroke cohort found that when comparing patients with none-to-mild WMH 
to those with severe WMH there was an increased risk for hip fractures (n = 383, follow-
up = 12 years) [185].  
2.2.7 White Matter Integrity and Motor-Gait Related Outcomes 
2.2.7.1 Cross-sectional Associations 
Four studies from five publications assessed WMI and gait velocity [188-191, 193]. A 
whole brain prospective cohort study (RUN-DMC; n = 485) examining the integrity of 
WMH and the normal-appearing white matter (NAWM) separately, reported significant 
associations between poor WMI of WMH and the NAWM and slower gait velocity [191]. 
In contrast, a tractography-based region-of-interest analyses study (n = 30) did not find 
significant associations between microstructural integrity and gait velocity in individuals 
with two types of parkinsonism or an age-matched control group [193]. The remaining 
three studies including two employing a ROI approach (n = 429 [190] and n = 16 [188]) 
and one using TBSS (n = 85 [189]) investigated poor regional WMI and gait velocity.  
Aside from gait velocity, three studies from four publications evaluated WMI and 
quantitative gait characteristics [186, 190, 191, 194]. A cohort study (n = 484) using a 
voxel-wise approach found significant association for integrity between both WMH and 
the NAWM and cadence and stride width whereas no association was found for stride 
time variability [191]. Moreover, stride length, double-support percentage, and stride 
time variability was reported in association for microstructural integrity of WMH but not 
for areas of the NAWM [191]. Regional correlates were identified for stride length [190], 
stride width [186, 190, 193] and cadence [190].  
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2.2.8 White Matter Integrity and Motor-Balance Related Outcomes 
2.2.8.1 Cross-sectional Association  
Two publications using TBSS and the same study cohort examined WMI and varying 
measures of postural sway [186, 187]. A significant association was reported between 
lower WMI and poor postural sway (n = 25) [186]. Upon further investigation, 
neuroanatomical locations of WMI and poor balance outcomes were also identified [186, 
187].  
2.2.9 White Matter Integrity and Motor-Composite Outcomes 
2.2.9.1 Cross-sectional Associations 
One study (n = 85) using TBSS evaluated WMI and SPPB outcomes [189]. Significant 
findings between poor WMI in the cerebral peduncles were reported in association for 
lower SPPB score.  
Another three studies assessed WMI and TUG scores [191, 194, 195]. A whole brain 
voxel-wise cohort study reported significant associations between WMI of both WMH 
and the NAMW and longer TUG completion time (RUN-DMC; n = 484) [191]. 
Additionally, a ROI analyses study (n = 38) detected significant associations for poor 
regional microstructural integrity and TUG completion time in individuals with INPH 
and PD [195]. In contrast, a whole brain voxel-wise study (n= 60) failed to find 
significant association between poor WMI and TUG completion time in individuals with 
INPH, however, significant associations were found for TUG number of steps [194]. 
Regional correlates of poor WMI in association for TUG number of steps were identified.  
Three studies examined WMI and Tinetti outcomes [155, 191, 192]. A voxel-wise 
approach study (n = 484) reported significant association between poor WMI of WMH 
and poor Tinetti outcomes but not for WMI of the NAWM [191]. The other two studies 
including a ROI approach study (n = 173 [155]) and a tractography-based ROI study (n = 
65 [192]) detected significant association between poor WMI in the corpus callosum and 
poor Tinetti performance.  
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2.2.10 White Matter Integrity and Adverse Motor Outcomes 
No studies evaluated the association between WMI and adverse motor outcomes. 
2.3 Discussion 
Our systematic review confirmed previous evidence that WMH burden is associated with 
poor motor performance in gait, balance, composite, and adverse motor outcomes among 
older adults. We extended this association to clinical samples, established longitudinal 
associations of WMH progression on motor outcomes and provided quantitative synthesis 
demonstrating a significant pooled-effect between higher WMH burden and slow gait 
velocity. More importantly, our results also indicate that microstructural changes to the 
WMI are associated with poor performance in motor-gait related and motor composite 
outcomes. 
To the authors’ knowledge, this is the first systematic review to provide a comprehensive 
evaluation of white matter abnormalities suggesting that microstructural alterations that 
predate the onset of WMH may have a pathological effect on motor performance. There 
were a large number of studies captured through the database search; however, we only 
identified a small number of studies examining white matter integrity and motor 
performance. The studies retrieved did not represent of our predefined outcomes of 
interest; one study from 2 publications evaluated motor-balance related outcomes and 
notably, no studies assessed adverse motor outcomes of falls or fractures. Furthermore, 
all studies investigating WMI were cross-sectional in design impeding our ability to 
dissociate the causal and temporal course of association. 
Previous studies have demonstrated that WMH are associated with an increased risk of 
stroke, dementia, and death in addition to executive function deficits [88, 114]. Here, we 
not only confirm the association of WMH on motor outcomes, but we also show 
compelling evidence of subtle alterations to the white matter microstructure in this 
association. This is of particular importance for two reasons; firstly, cognitive and motor 
outcomes are postulated to be interrelated entities, with motor outcomes often preceding 
the onset of clinically significant cognitive outcomes progressing to neurodegenerative 
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conditions and dementia syndromes [8, 32, 196]; and secondly, because changes to the 
white matter microstructure precedes the onset of visible WMH [112, 146, 147]. Taken 
together, it is plausible to postulate that there is a continuum from disruption in WMI to 
WMH burden found in the association with age-related motor decline and 
neurodegeneration. This evidence suggests that white matter abnormalities, as a potential 
modifiable risk factor, can be a target of early interventions aimed at attenuating physical 
decline. Future studies are needed to test this hypothesis in light of a few methodological 
considerations. 
Studies employing the use of diffusion-tensor imaging, specifically TBSS and 
tractography approaches capable of solving voxel and spatial alignment issues, were 
limited. Two studies from three publications examined diffusion parameters aside from 
fractional anisotropy to characterize white matter tissue microstructure [189-191]. 
Moreover, only one study evaluated the microstructural properties of the NAMW and 
WMH, separately, in association to motor performance [191]. In order to elucidate 
patterns in white matter alterations leading to physical consequences, these shortcomings 
need to be addressed. 
Anatomical regional correlates of white matter abnormalities in relation to motor 
outcomes were assessed across a large number of studies. Due to considerable 
heterogeneity in imaging standards and analysis between studies, no clear patterns of 
association emerged. Typically, issues of inconsistent terminology and method of 
classification were common and precluded our ability to synthesize regional correlates.  
While the evidence summarized in our review examines structural brain changes, we 
postulate that patterns in motor performance may also be a result of compensatory 
strategies of increased activation [197, 198]. Such brain activations are facilitated through 
the use of functional neuroimaging methods. A recent systematic review examining brain 
activity during walking found that with aging and in various clinical populations, there 
were various compensatory mechanisms that aided stable walking [199]. This may 
explain why clinical symptoms and consequences of white matter abnormalities affect 
individuals heterogeneously.  
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2.3.1 Study Highlights and Limitations 
Although our study consisted of a comprehensive search strategy examining both visible 
and subtle white matter changes across healthy and clinical populations, there are several 
limitations that must be recognized. Firstly, lack of reporting consistency in non-
significant results across studies meant that most outcomes could not be meta-analyzed 
subjecting our review to reporting bias. Secondly, in instances where studies were meta-
analyzed the methodologies of different variables varied considerably (e.g., MRI 
resolution, contrast). Lastly, our stringent definition of motor performance-based 
outcomes led to the exclusion and underrepresentation of most studies comprising of PD 
cohorts. 
2.4 Conclusion 
In conclusion, our research synthesis provides evidence that WMH burden is associated 
with poor motor performance and adverse motor outcomes, cross-sectionally and 
longitudinally, in general and clinical samples. Emerging evidence synthesized also 
supports that early white matter changes, evaluated as WMI, may have a pathological 
burden on motor performance. Future studies employing DTI techniques are required to 
understand the role of WMI on motor-balance and adverse motor outcomes, in addition to 
deciphering the longitudinal association of microstructural changes.  
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Chapter 3  
3 Moderating Effect of Physical Activity on White Matter 
Hyperintensities and Quantitative Gait Characteristics  
Mobility impairment as manifested by changes in gait characteristics are common in 
older individuals [1, 2]. These changes have a significant impact on an individual’s 
functional independence and overall quality of life [1]. Converging evidence highlights 
the underlying role of white matter hyperintensities (WMH) in association for changes in 
gait characteristics (see Chapter 2 for review) [3-5]. Although the pathophysiology of 
WMH is complex, it is postulated that they are associated with cardiovascular risk factors 
[6]. Therefore, strategies aimed at improving these risk factors may also attenuate the 
effect of WMH burden on gait characteristics.  
Physical activity is a modifiable lifestyle factor with the protective ability to influence 
brain, cardiovascular and physical functioning [7-9]. Few studies to date have examined 
the role of physical activity on the association between WMH and gait outcomes [10]. 
The purpose of this study was to 1) examine the independent association between WMH 
and gait velocity and stride time variability under single and dual-task conditions in a 
geriatric clinic sample, and 2) to examine if this relationship is moderated by physical 
activity.  
3.1 Methods 
3.1.1 Study Participants 
The Gait and Brain Study is an ongoing prospective cohort study initiated to determine 
whether quantitative gait characteristics can predict cognitive and mobility decline, and 
progression to dementia among community-dwelling older adults. Recruitment was 
carried out through geriatric clinics in London, Ontario, which increased the probability 
of enrolling participants with cognitive impairments. This study comprised a subsample 
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of cohort members who participated in neuroimaging data collection. Study design and 
logistics have been detailed in previous publications [11-13]. Additional information can 
be found at clinicaltrial.gov under study identifier NTC03020381. 
After written informed consent was obtained, participants underwent a comprehensive 
baseline assessment and returned on a biannual basis for follow-up over 3 years and 
annually for a subsequent 7 years, reaching a total of 10 years of follow-up.  
To be included in this analysis, participants needed to complete a neuroimaging session at 
one of three time-points of during follow-up. Participants were community-living 
meeting the following inclusion criteria: (1) aged 65 years and older; (2) English 
speaking; (3) able to ambulate 10 meters independently without the use of a walking aid. 
Exclusion criteria were: (1) parkinsonism or other neurological condition with residual 
motor deficit; (2) musculoskeletal disorder affecting lower limbs; (3) use of psychotropic 
medications (i.e., neuroleptics and/ or benzodiazepines); and (4) major depression 
disorder.  
The Gait and Brain Study protocol was approved from the University of Western Ontario 
Research Ethics Board for Health Sciences Research Involving Human Subjects (see 
Appendix B). Data collection occurred between December 2012 and May 2017.  
3.1.2 Assessment of Clinical and Cognitive Functions 
Participants were interviewed on sociodemographic characteristics, comorbidities (i.e., 
diabetes, hypertension, angina, myocardial infarction, stroke, Parkinson’s disease, 
chronic lung disease, depression), medications and history of falls. Basic and 
instrumental activities of daily living were evaluated using the Lawton-Brody Scale [14]. 
Physical and neurological examination in all participants was carried out by the study 
clinician. 
Global cognitive functioning was assessed using the Mini-Mental State Examination 
(MMSE) [15] and the Montreal Cognitive Assessment (MoCA) [16]. A comprehensive 
neuropsychological battery was also administered to assess specific cognitive domains; 
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executive functions – Trail Making Test (TMT) A and B [17]; verbal episodic memory – 
Rey Auditory Verbal Learning Test (RAVLT) [18]; attention – Digit Span Test (forward 
and backward) and attention and working memory – Letter Number Sequence (LNS) 
[19].  
3.1.3 Assessment of Gait 
Gait under single and dual-task conditions was assessed using a computerized walkway 
(GAITRite© Systems, 600 cm long and 65 cm wide; CIR Systems, Havertown, PA 
USA). Start and end points were marked 1 meter from either end of the walkway to avoid 
recording acceleration and deceleration phases. For single-task gait testing, participants 
were asked to ambulate at their “normal pace” wearing comfortable footwear in a well-lit, 
quiet room. For dual-task gait testing, participants were asked to complete the following 
cognitive task aloud: (1) counting backwards by one; (2) counting backwards by seven 
(serial seven); and (3) naming animals. One trial was performed of each dual-task 
conditions in order to balance and minimize the effects of learning and fatigue.  
3.1.4 Assessment of Physical Activity  
Physical activity was measured using the Physical Activity Scale for the Elderly (PASE). 
The PASE is a valid and reliable self-reported measure of physical activity among older 
adult [20, 21]. It comprises of 10-items examining domains of walking, sport and 
recreational activities, leisure time activities, housework, and work-related activity during 
the previous one-week period. The PASE also includes an item assessing sitting activities 
such as reading, watching TV or doing handcrafts, but it was excluded as it does not 
reflect physical activity. Total PASE score is calculated by assigning a specific weight for 
each item based on time spent in each activity (hours per week) or general participant 
(i.e., yes or no). Higher scores indicate higher levels of physical activity. 
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3.1.5 Neuroimaging Data Acquisition 
Imaging of the brain was performed at Robarts Research Institute Centre for Functional 
and Metabolic Imaging using a 3.0-T MRI scanner (Siemens, Erlangen, Germany). High 
resolution images were collected using a standard protocol including 3D T1-weighted 
magnetization-prepared rapid acquisition gradient echo (MPRAGE) sagittal images 
(acquisition matrix = 256 x 240 x 160, FOV = 240 mm x 256 mm x 192 mm, TR = 2.3 s, 
TE = 2.91 ms, T1 = 900 ms, flip angle = 9°, average = 1), fluid-attenuated inversion 
recovery (FLAIR) coronal images (acquisition matrix = 256 x 232, reconstruction to 512  
x 464 matrix, FOV = 220 mm x 200 mm, thickness = 4 mm, gap = 0.5 mm, 41 slices, TR 
8 s, TE = 120 ms, T1 = 2400 ms, flip angle = 130°, averages = 1).   
3.1.6 Neuroimaging Data Processing 
White matter hyperintensities were segmented automatically using the lesion growth 
algorithm [22] as implemented in the Lesion Segmentation Tool (LST) toolbox version 
1.2.3 (www.statistical- modelling.de/lst.html) for Statistical Parametric Mapping Version 
8 (SPM 8). First, T1 images are segmented into three main tissue classes (cerebrospinal 
spinal fluid, grey matter and white matter). These tissue classes are then combined with 
the co-registered FLAIR images to calculate lesion belief maps. Next, through 
thresholding these lesion belief maps (threshold κ = 0.3) a binary lesion map is obtained, 
which is subsequently grown along the voxels that appear as hyperintensities within the 
FLAIR images resulting in a lesion probability maps. See Appendix C for the flow 
diagram of the lesion segmentation algorithm.     
As intracranial volume (ICV) is an important covariate for volumetric analyses of the 
brain, estimated ICV was determined using the FreeSurfer software, version 5.3.0 
(http://surfer.-nmr.mgh.harvard.edu/). Briefly, FreeSurfer determines ICV from T1 
images using an atlas scaling factor derived from registering images to an average 
template through a full affine transformation (12-parameter) [23]. WMH volume used in 
the present study was the adjusted volume by ICV, calculated as a percentage [24].  
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3.1.7 Outcome Measures 
Quantitative gait characteristics of gait velocity and stride time variability under single 
and dual-task conditions (counting, serial seven and naming animals) were the main 
outcomes of interest. These outcome measures were all modelled as continuous variables.   
3.1.8 Predictor Measures  
Volumetric measure of WMH burden was the main predictor, as previous studies have 
demonstrated a relationship with gait outcomes (see Chapter 2 for review). WMH burden 
was modeled as a continuous and was calculated as a percentage of intracranial volume.    
3.1.9 Covariates  
Analyses were adjusted for age, sex, cognitive functioning as assessed by the MoCA and 
vascular risk factors. Vascular burden was attained using a vascular risk factor index 
comprising of seven items including hypertension, dyslipidemia, diabetes mellitus, 
history of coronary artery disease, stroke, chronic heart failure and atrial fibrillation. 
These covariates were determine a priori based on the known influence on physical 
activity and WMH burden. 
3.1.10 Statistical Analysis 
Demographic characteristics and scores from gait and cognitive testing were summarized 
using either means and standard deviations or frequencies and percentage, as appropriate. 
Participants were stratified according to tertiles using a rank cases approach based on 
levels of global cognitive functions (MoCA), executive functions (TMT B) and physical 
activity (PASE) in efforts to better characterize our study sample. Comparisons across 
stratified groups for continuous outcomes were made using analysis of variance 
(ANOVA), and where unequal variance was detected, Welch’s Test. Chi-square tests 
were used for categorical measures. A series of linear regression models were constructed 
to examine the association between WMH burden and gait velocity and stride time 
variability under single and dual-task conditions. Because the distribution of WMH 
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volume and stride time variability was skewed, it was log transformed to normalize 
distribution. See Appendix D for transformations of non-normally distributed variables. 
Moderation analysis examining the interaction between WMH and physical activity was 
conducted using the PROCESS SPSS Macros version 2.16.3 (Model 1), based on the 
ordinary least squares analytic framework [25]. WMH volume was entered into the 
model as a predictor variable and physical activity was entered as the moderator variable. 
Variables were mean centered prior to model entry. Participant age, sex and MoCA 
scores were entered as covariates. To test for significant differences in the effect of 
physical activity on the criterion variables at ±1 SD and mean, a conditional simple 
slopes analysis was utilized. To further examine the interactions, the Johnson-Neyman 
technique was used to examine how the relationship between WMH and gait changed 
across the continuum of physical activity [26].  
Statistical significance was set at p ≤ 0.05 (two-sided). All analyses were conducted using 
SPSS, version 24 (IBM Corporation, Chicago, IL USA). 
3.2 Results  
3.2.1 Participant Characteristics  
Fifty-nine participants (mean age = 74.24 years ± 5.53; 40.7% women) with MRI were 
included in this analysis. Briefly, mean MoCA score was 23.58 ± 3.74 (range = 12–30), 
WMH volume was 34.44 ± 26.2 mL (range = 4.9–110.32 mL) and PASE score was 94.18 
± 41.57 (range = 27.53–205.34). Detailed characteristics of study sample, stratified by 
global cognitive functioning, executive functioning and physical activity are presented in 
Table 3.1, 3.2 and 3.3, respectively. 
One-way ANOVA comparing participants across MoCA and TMT B stratum indicated 
that participants across the tertiles differed in MMSE, MoCA, TMT A and B, digit span 
backwards, RAVLT, LNS, single-task gait velocity, dual-task counting and naming 
animals gait velocity (p < 0.05). Strata of TMT B scores also indicated that participants 
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across the tertiles differed in age, WMH volume, dual-task serial seven gait velocity, and 
dual-task counting gait stride time variability (p < 0.05). In addition, comparing 
participants across PASE strata indicated that the tertiles differed in presence of 
hypertension, vascular risk factors and physical activity scores (p < 0.05). 
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Table 3.1 Baseline characteristics of participants stratified according to tertiles of 
Montreal Cognitive Assessment scores (n = 59) 
  Stratified by MoCAa  
Variable Full Cohort  
(n = 59) 
Low 
(n = 18) 
Moderate 
(n = 20) 
High 
(n = 21) 
P-value 
Age, mean (SD), years 74.24 (5.53) 76.06 (5.72) 74.55 (5.59) 72.38 (4.95) 0.11 
Women, n (%) 24 (40.7) 6 (33.3) 12 (60) 6 (28.6) 0.09 
Education, mean (SD), 
years 
13.75 (2.78) 13.33 (2.68) 13.15 (2.25) 14.67 (3.18) 0.16 
BMI, mean (SD), kg/m2 26.91 (4.46) 25.14 (3.93) 27.59 (4.54) 27.79 (4.57) 0.13 
No. of Medications, mean 
(SD) 
7.49 (4.68) 7.78 (4.87) 9 (5.24) 5.81 (3.47) 0.09 
No. of Comorbidities, 
mean (SD) 
5.56 (2.64) 5.83 (2.12) 5.1 (3.16) 5.76 (2.57) 0.64 
Comorbidities, n (%)      
Hypertension 27 (45.8) 8 (44.4) 10 (50) 9 (42.9) 0.89 
Dyslipidemia 27 (45.8) 9 (50) 8 (40) 10 (47.6) 0.81 
Smoking 28 (47.5) 9 (50) 8 (40) 11 (52.4) 0.71 
Osteoarthritis 21 (35.6) 6 (33.3) 10 (50) 5 (23.8) 0.21 
MMSE, mean (SD) 27.53 (2.52) 25.5 (3.07) 27.85 (1.76) 28.95 (1.24) <0.001 
MoCA, mean (SD) 23.58 (3.74) 19.28 (2.49) 23.45 (1.05) 27.38 (1.53) <0.001 h 
VRF index, mean (SD) 1.36 (1.17) 1.33 (1.1) 1.5 (1.36) 1.24 (1.1) 0.78 
BP Systolic, mean (SD), 
mmHg 
128.51 (13.16) 124.61 (13.92) 130.6 (12.89) 129.86 (12.65) 0.32 
BP Diastolic, mean (SD), 
mmHg 
74.68 (11.37) 71.22 (8.68) 76.6 (14.25) 75.81 (10.10) 0.3 
PASE, mean (SD)b 94.18 (41.57) 91.16 (42.04) 87.18 (47.21) 103.45 (35.29) 0.43 
WMH, mean (SD), mL 36.44 (26.2) 44.99 (28.1) 34.69 (23.5) 30.78 (26.32) 0.23 
Cognition, mean (SD)      
TMT A, seconds 44.81 (18.38) 56.61 (21.73) 43.62 (15.15) 35.83 (12.18) 0.004h 
TMT B, seconds 142.94 (176.06) 260.05 (286.57) 101.37 (43.92) 82.14 (17.44) 0.02h 
Digit span forward 10.58 (2.47) 10.28 (2.19) 10.6 (2.93) 10.81 (2.32) 0.8 
Digit span backward 6.22 (2.36) 5.17 (1.98) 5.7 (2.27) 7.62 (2.13) 0.002 
RAVLTc 5.67 (3.52) 4.41 (2.9)e 4.35 (3.27) 7.95 (3.15) <0.001 
LNS 7.92 (3.14) 6.28 (3.08) 7.75 (3.04) 9.48 (2.58) 0.005 
Gait, mean (SD)      
Gait Velocity, cm/s      
Single-task 109.64 (20.28) 99.62 (19.29) 105.61 (17.67) 122.07 (17.64) 0.001 
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Counting 103.86 (24.64) 90.9 (23.01) 100.13 (21.79) 118.53 (21.66) 0.001 
Serial Sevens 92.56 (27.1) 84.48 (29.17)e 87.83 (19.03) 103.61 (29.36) 0.06 
Naming 
Animals 
94.3 (26.62) 84.15 (26.49) 89.43 (21.99) 107.63 (26.39) 0.01 
Stride Time 
Variability, CoV, % 
     
Single-task 2.23 (0.83) 2.32 (0.47)d 2.38 (1.01)g 2 (0.84)g 0.34 
Counting 2.97 (1.78) 3.54 (1.77) 3.07 (1.53) 2.39 (1.91) 0.13 
Serial Sevens 4.65 (4.45) 6.73 (6.67)e 3.77 (1.9) 3.81 (3.48) 0.23h 
Naming 
Animals 
3.4 (1.76) 3.84 (1.96)e 3.35 (1.94)f 3.05 (1.37)g 0.41 
Note: Statistically significant associations are presented in bold-type font. 
Abbreviations: BMI, body mass index. BP, blood pressure. CoV, coefficient of variation. 
LNS, Letter Number Sequencing. MMSE, Mini Mental State Examination. MoCA, 
Montreal Cognitive Assessment. PASE, Physical Activity Scale in the Elderly. RAVLT, 
Rey Auditory Verbal Learning Test. SD, standard deviation. TMT A, Trail Making Test. 
TMT B, Trail Making B. VRF, Vascular Risk Factor. WMH, white matter 
hyperintensities.  
a, Low MoCA scores denotes poor performance in global cognitive functioning. 
b, PASE score excluding items 1 and 10. 
c, Final score is number of words remember out of a list of 15 in trial 6 (delayed recall). 
d, Data available for n = 16. 
e, Data available for n = 17. 
f, Data available for n = 18. 
g, Data available for n = 19. 
h, p-values reported from Welch’s Test for unequal variance. 
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Table 3.2 Baseline characteristics of participants stratified according to tertiles of 
Trail Making Test B scores (n = 59) 
  Stratified by TMT Ba  
Variable Full Cohort  
(n = 59) 
Low  
(n = 20) 
Moderate 
(n = 20) 
High  
(n = 19) 
P-
value 
Age, mean (SD) 74.24 (5.53) 76.75 (5.78) 73.4 (5.34) 72.47 (4.71) 0.04 
Women, n (%) 24 (40.7) 8 (40) 6 (30) 10  (52.6) 0.36 
Education, mean (SD), years 13.75 (2.78) 13.55 (2.63) 13.55 (3.05) 14.16 (2.75) 0.74 
BMI, mean (SD), kg/m2 26.91 (4.46) 26.52 (4.2) 27.39 (4.65) 26.82 (4.72) 0.83 
No. of Medication, mean (SD) 7.49 (4.68) 9.5 (4.99) 6.5 (5.42) 6.42 (2.57) 0.06 
No. of Comorbidities, mean (SD) 5.56 (2.64) 5.7 (3.06) 5.65 (2.16) 5.32 (2.75) 0.89 
Comorbidities, n (%)      
Hypertension 27 (45.8) 9 (45) 7 (35) 11 (57.9) 0.36 
Dyslipidemia 27 (45.8) 8 (40) 7 (35) 12 (63.2) 0.17 
Smoking 28 (47.5) 8 (40) 12 (60) 8 (42.1) 0.38 
Osteoarthritis 21 (35.6) 11 (55) 5 (25) 5 (26.3) 0.08 
MMSE, mean (SD) 27.53 (2.52) 25.95 (3.17) 27.95 (1.85) 28.74 (1.33) 0.004g 
MoCA, mean  (SD) 23.58 (3.74) 20.65 (3.63) 24.9 (3.14) 25.26 (2.49) <0.001 
VRF Index, mean (SD) 1.36 (1.17) 1.2 (1.11) 1.3 (1.45) 1.58 (0.9) 0.59 
BP Systolic, mean (SD), mmHg 128.51 (13.16) 124.85 (12.08) 131.85 (13.29) 128.84 (13.8) 0.24 
BP Diastolic, mean (SD), mmHg 74.68 (11.37) 70.6 (8.36) 77.35 (12.84) 76.16 (11.84) 0.14 
PASE, mean (SD)b 94.18 (41.57) 89.58 (36.4) 100.07 (42.5) 92.83 (46.91) 0.72 
WMH, mean (SD), mL 36.44 (26.2) 47.63 (28.27) 38.79 (28.3) 22.18 (12.76) 0.001g 
Cognition, mean (SD)      
TMT A, seconds 44.81 (18.38) 58.05 (22.51) 40.61 (9.6) 35.29 (12.08) 0.002g 
TMT B, seconds 142.94 (176.06) 263.01 (266.69) 94.42 (8.11) 67.61 (10.64) <0.001g 
Digit Span Forward 10.58 (2.47) 9.9 (2.34) 11.1 (2.51) 10.74 (2.54) 0.3 
Digit Span Backward 6.22 (2.36) 4.9 (1.71) 6.25 (2.12) 7.58 (2.48) 0.001 
RAVLTc  5.67 (3.52) 3.63 (2.69)f 6.5 (2.98) 6.84 (4) 0.006 
LNS 7.92 (3.14) 5.55 (2.68) 8.7 (2.99) 9.58 (2.19) <0.001 
Gait, mean (SD)       
Gait Velocity, cm/s      
Single-task 109.64 (20.28) 95.9 (19.23) 119.23 (17.55) 114.02 (16.65) <0.001 
Counting 103.86 (24.64) 85.81 (21.24) 114.34 (19.43) 111.84 (23.04) <0.001 
Serial Sevens 92.56 (27.1) 77.9 (24.71)f 100.70 (23.41) 98.67 (28.22) 0.01 
Naming Animals 94.3 (26.62) 77.91 (22.92) 102.18 (24.58) 103.26 (25.28) 0.002 
Stride time variability, CoV, 
% 
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Single-task 2.23 (0.83) 2.34 (0.63)e 2.14 (0.79)e 2.21 (1.04)e 0.76 
Counting 2.97 (1.78) 3.78 (1.73) 2.69 (1.36) 2.43 (1.99) 0.04 
Serial Sevens 4.65 (4.45) 6.44 (6.32)f 3.16 (2.28) 4.44 (3.36) 0.08g 
Naming Animals 3.4 (1.76) 3.57 (2.07)e 3.37 (1.66)f 3.26 (1.6)d 0.88 
Note: Statistically significant associations are presented in bold-type font. 
Abbreviations: BMI, body mass index. BP, blood pressure. CoV, coefficient of variation. 
LNS, Letter Number Sequencing. MMSE, Mini Mental State Examination. MoCA, 
Montreal Cognitive Assessment. PASE, Physical Activity Scale in the Elderly. RAVLT, 
Rey Auditory Verbal Learning Test. SD, standard deviation. TMT A, Trail Making Test. 
TMT B, Trail Making B. VRF, Vascular Risk Factor. WMH, white matter 
hyperintensities.  
a, Low TMT B scores denotes poor performance in executive functioning. 
b, PASE score excluding items 1 and 10. 
c, Final score is number of words remember out of a list of 15 in trial 6 (delayed recall). 
d, Data available for n = 17. 
e, Data available for n = 18. 
f, Data available for n = 19. 
g, p-values reported from Welch’s Test for unequal variance. 
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Table 3.3 Baseline characteristics of participants stratified according to tertiles of 
Physical Activity Scale for the Elderly scores (n = 59) 
  Stratified by PASEd  
Variable Full Cohort  
(n = 59) 
Low 
(n = 19) 
Moderate  
(n = 20) 
High 
 (n = 20) 
P-
values 
Age, mean (SD) 74.24 (5.53) 75.84 (6.36) 74.1 (5.15) 72.85 (4.89) 0.24 
Women, n (%) 24 (40.7) 9 (45) 9 (45) 6 (30) 0.48 
Education, mean (SD), years 13.75 (2.78) 13.63 (2.59) 14 (3.13) 13.6 (2.72) 0.88 
BMI, mean (SD), kg/m2 26.91 (4.46) 27.25 (5.07) 27.18 (4.68) 26.33 (3.73) 0.78 
No. of Medication, mean (SD) 7.49 (4.68) 7.95 (2.95) 7 (5.18) 7.55 (5.61) 0.82 
No. of Comorbidities, mean 
(SD) 
5.56 (2.64) 5.95 (2.78) 5.1 (3.04) 5.65 (2.08) 0.6 
Comorbidities, n (%)      
Hypertension 27 (45.8) 13 (68.4) 8 (40) 6 (30) 0.045 
Dyslipidemia 27 (45.8) 11 (57.9) 6 (30) 10 (5) 0.2 
Smoking 28 (47.5) 10 (52.6) 9 (45) 9 (45) 0.86 
Osteoarthritis 21 (35.6) 8 (42.1) 7 (35) 6 (30) 0.73 
MMSE, mean (SD) 27.53 (2.52) 27.58 (2.04) 27.5 (2.46) 27.5 (3.07) 0.99 
MoCA, mean (SD) 23.58 (3.74) 23.11 (3.28) 23.6 (4.41) 24 (3.55) 0.76 
VRF Index, mean (SD) 1.36 (1.17) 1.84 (1.26) 1 (0.97) 1.25 (1.16) 0.07 
BP Systolic, mean (SD), 
mmHg 
128.51 (4.46) 131.68 (19.24) 126.65 (7.61) 127.35 (10.25) 0.58i 
BP Diastolic, mean (SD), 
mmHg 
74.68 (11.37) 77.21 (14.38) 72.45 (8.12) 74.5 (11) 0.43 
PASE, mean (SD)b 94.18 (41.57) 48.98 (12.94) 91.44 (15.57) 139.88 (25) <0.001i 
WMH, mean (SD), mL 36.44 (26.2) 46.38 (32.17) 30.63 (21.70) 32.81 (22.28) 0.13 
Cognition, mean (SD)      
TMT A, seconds 44.81 (18.38) 43.55 (16.83) 47.81 (22.39) 43.01 (15.71) 0.67 
TMT B, seconds 142.94 (176.06) 104.91 (51.87) 166.41 (207.83) 155.59 (216.07) 0.52 
Digit Span Forward 10.58 (2.47) 10.21 (1.99) 10.2 (2.44) 11.3 (2.85) 0.28 
Digit Span Backward 6.22 (2.36) 5.68 (1.16) 6.65 (3.01) 6.3 (2.47) 0.32i 
RAVLTc  5.67 (3.52) 5.26 (3.28) 5.85 (4.16) 5.89 (3.16)g 0.83 
LNS 7.92 (3.14) 7.79 (1.9) 7.75 (3.84) 8.2 (3.43) 0.89i 
Gait, mean (SD)      
Gait Velocity, cm/s      
Single-task 109.65 (20.28) 102.64 (19.99) 109.17 (21.41) 116.76 (17.78) 0.09 
Counting 103.86 (24.64) 94.09 (25.87) 104.97 (23.97) 112.05 (21.87) 0.07 
Serial Sevens 92.56 (27.1) 82.88 (26.32) 95.77 (28.25) 98.87 (25.25)g 0.16 
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Naming Animals 94.3 (26.62) 85.16 (24.29) 95.16 (28.62) 102.12 (25.22) 0.14 
Stride Time Variability, 
CoV, % 
     
Single-task 2.23 (0.83) 2.48 (0.9)e 2.07 (0.75) 2.16 (0.83)e 0.29 
Counting 2.97 (1.78) 3.7 (2.04) 2.63 (1.55) 2.63 (1.6) 0.1 
Serial Sevens 4.65 (4.45) 4.64 (4.23) 4.94 (5.09) 4.36 (4.14)g 0.92 
Naming Animals 3.4 (1.76) 4.12 (1.71)d 2.9 (1.31)f 3.27 (2.03) 0.12 
Note: Statistically significant associations are presented in bold-type font. 
Abbreviations: BMI, body mass index. BP, blood pressure. CoV, coefficient of variation. 
LNS, Letter Number Sequencing. MMSE, Mini Mental State Examination. MoCA, 
Montreal Cognitive Assessment. PASE, Physical Activity Scale in the Elderly. RAVLT, 
Rey Auditory Verbal Learning Test. SD, standard deviation. TMT A, Trail Making Test. 
TMT B, Trail Making B. VRF, Vascular Risk Factor. WMH, white matter 
hyperintensities.  
a, Low PASE scores denotes low levels of self-reported physical activity. 
b, PASE score excluding items 1 and 10. 
c, Final score is number of words remember out of a list of 15 in trial 6 (delayed recall) 
d, Data available for n = 16. 
e , Data available for n = 17. 
f, Data available for n = 18. 
g, Data available for n = 19. 
h, Data available for n = 20. 
i, p-values reported from Welch’s Test for unequal variance.
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3.2.2 Association between White Matter Hyperintensities and Gait  
Multiple linear regression analyses were used to test if WMH volume predicted gait 
velocity under single and dual task conditions, after controlling for covariates of age, sex, 
MoCA and vascular risk factor (see Table 3.4). In unadjusted models, WMH was 
significantly associated with single and dual-task gait velocity. After adjusting for age, 
sex and MoCA, only single-task gait velocity remained significant (standardized β = -
0.32, 95% CI = -17.8, -1.76, p = 0.018). In the final model including vascular risk factors, 
the effect of WMH on single-task gait velocity was no longer significant (standardized β 
= -0.23, 95%CI -14.73, 0.8, p = 0.08).  
There were no significant associations between measures of WMH and stride time 
variability under single and dual-task conditions (see Table 3.5).  
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Table 3.4: Linear regression models for the association between white matter hyperintensities and gait velocity under single 
and dual-task conditions 
 Single-task Counting  Serial 7 Naming animals  
 β p 95% CI β p 95% CI β p 95% CI β p 95% CI 
Model 1 -0.42  0.001 -19.79, -5.23 0.1  0.01 -20.92, -2.49 -0.3  0.02 -22.42, -1.84 -0.29  0.02 -21.9, -1.62 
Model 2 -0.32  0.02 -17.8, -1.76 -0.17  0.2 -16.04, 3.35 -0.18  0.21 -18.97, 4.18 -0.15  0.27 -16.96, 4.84 
Model 3 -0.23  0.08 -14.73, 0.8 -0.09 0.48 -12.94, 6.18 -0.11  0.46 -15.8, 7.3 -0.07 0.63 -13.27, 8.11 
Model 1: unadjusted. 
Model 2: age, sex, and MoCA. 
Model 3: model 2 plus adjustment for vascular risk factors. 
Values are standardized β (95% CI).  
Note: Statistically significant associations are presented in bold-type font. WMH are calculated as a percentage of intracranial volume 
and log-transformed. 
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Table 3.5: Linear regression models for the association between white matter hyperintensities and stride time variability 
under single and dual-task conditions 
 Single-task Counting  Serial 7 Naming animals  
 β p 95% CI β p 95% CI β p 95% CI β p 95% CI 
Model 1 0.22  0.1 -0.03, 0.27 0.22  0.1 -0.03, 0.38 0.1  0.44 -0.18, 0.41 -0.1  0.49 -0.29, 0.14 
Model 2 0.21  0.2 -0.62, 0.29 0.21  0.17 -0.07, 0.41 0.05 0.74 -0.29, 0.41 -0.12  0.46 -0.35, 0.16 
Model 3 0.18 0.3 -0.09, 0.28 0.2  0.2 -0.09, 0.42 0.01  0.97 -0.36, 0.37 -0.15  0.38 -0.39, 015 
Model 1: unadjusted. 
Model 2: age, sex, and MoCA. 
Model 3: model 2 plus adjustment for vascular risk factors. 
Values are standardized β (95% CI).  
Note: Statistically significant associations are presented in bold-type font. WMH are calculated as a percentage of intracranial volume 
and log-transformed. 
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3.2.3 Moderation of Physical Activity on White Matter 
Hyperintensities and Gait 
For our moderation analysis, the overall model was significant (F (6, 52) = 6.12, p = 
0.001) and accounted for 36.36% of the variance in gait velocity, see Table 3.6. There 
was a significant association for MoCA scores (b = 1.56, p = 0.03), entered into the 
model as a covariate, and gait velocity but not for age (b = -0.44, p = 0.4) and sex (b = -
4.67, p = 0.34). Results also indicated that there was significant main effect of WMH 
volume (b = -9.12, p = 0.01), but not PASE (b = 0.09, p = 0.12). Further, the interaction 
term, which accounted for 1% of the variance in gait velocity (F (1, 52) = 6.12, p = 0.39) 
was not significant.  
Figure 3.1 illustrates the model-based estimations of the simple slopes regression line 
showing the relation between WMH volume and gait velocity at three levels of the 
moderator (PASE scores): mean and ±1 SD from the mean of the PASE.  Results 
indicated that WMH burden was significantly associated with gait speed in participants 
with low (-1 SD; t = -2.54, p = 0.01, b = -11.63) and moderate (mean; t = -2.92, p = 
0.01, b = -9.12) levels of physical activity, but not for those with high (+1 SD; t = -1.7, p 
= 0.1, b = -6.61) levels of physical activity, see Table 3.7. Further inspection using the 
Johnson-Neyman technique showed that increases in WMH volume negatively predicted 
gait velocity when PASE scores were ≤ 127, which included 81.36% of our sample. 
However, when PASE scores were > 127, WMH volume no longer predicted gait 
velocity.  
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Table 3.6 Linear regression models with main and moderating effect for white 
matter hyperintensities and physical activity with single-task gait velocity 
Predictor Effect [95% CI] SEb P-value 
Age  -0.44 [-1.47, 0.59] 0.51 0.4 
Sex -4.67 [-14.34, 4.99] 4.82 0.34 
MoCA 1.56 [0.18, 2.94] 0.69 0.03 
WMH -9.12 [-15.38, -2.86] 3.12 0.01 
PASE 0.09 [-0.02. 0.2] 0.05 0.12 
WMH x PASE 0.06 [-0.08. 0.2] 0.07 0.39 
Abbreviations: b, coefficient. MoCA, Montreal Cognitive Assessment. PASE, Physical 
Activity for the Elderly. SE, standard error. WMH, white matter hyperintensities. 
Note: Statistically significant associations are presented in bold-type font. WMH are 
calculated as a percentage of intracranial volume. 
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Figure 3.1 Conditional association between white matter hyperintensities and usual 
gait velocity at different levels of the Physical Activity Scale for the Elderly.  
Table 3.7 Conditional effects of physical activity on the association between white 
matter hyperintensities and single task gait velocity 
Physical Activity b [95% CI] SEb P-value 
One SD below mean -11.63 [-20.81, -2.45] 4.57 0.01 
At the mean -9.12 [-15.38, -2.86] 3.12 0.01 
One SD above mean -6.61 [-14.41, 1.19] 3.39 0.1 
Note: Statistically significant associations are presented in bold-type font. 
Abbreviations: b, coefficient. CI, confidence interval. 
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3.3 Discussion 
In our study, we found that higher WMH burden was independently associated with 
slower single-task gait velocity, but not with measures of stride time variability or dual-
task gait velocities, in a well-characterized geriatric clinic sample. In addition, while our 
moderation analysis did not show overall significance, the results of the simple slopes 
analyses provide evidence to suggest that low and moderate levels of physical activity 
modified the association between WMH burden and gait velocity. More specifically, this 
association was only significant when participants had PASE scores that were ≤ 127. 
These results indicate that physical activity may play a role in attenuating the effect of 
WMH burden on gait performance in older individuals. 
White matter pathways are a central component of frontal subcortical networks proposed 
to underlie gait control and cognitive functions. Previous studies have demonstrated that 
WMH burden are associated with slower gait velocity, a finding that was confirmed in 
our sample [27, 28]. Moreover, the significant effect of WMH on single-task gait velocity 
was attenuated when vascular risk factors were included as covariates. Noteworthy, 
however, WMH did not show significant associations with gait velocity under dual-task 
conditions findings that were also in agreement with the extant literature [29-31].  
In efforts to explain our non-significant findings under dual-task conditions, we postulate 
that WMH impact gait velocity under single and dual task conditions via different 
pathways. The underlying mechanisms of gait performance under dual-task conditions 
are not completely understood, although this association is increasingly supported by 
convergent evidence for the role of executive functions [32]. In a study by Zheng and 
colleagues [33], it was shown that the association between WMH and a functional test 
(i.e. choice stepping reaction time) under dual-task conditions was mediated through 
neuropsychological functioning. Another study extending on these findings proposed a 
theoretical pathway through which WMH may negatively impact gait performance. The 
two main proposed pathways were: (1) the direct locomotor pathway, in which WMH 
disrupts mobility-related pathways; and (2) the indirect locomotor pathway, in which 
WMH disrupts circuits responsible for cognitive functions leading to impaired mobility 
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[34]. Furthermore, this study found that when examining the direct pathway, WMH 
explained a significant 72% of the variance in gait velocity and the indirect pathway 
through executive functions, but not global cognition, explained a significant 19% of the 
variance in gait velocity [34].  
Considering the aforementioned, it is plausible that taxing an individual’s attention 
resources while walking deviates from the direct to the indirect pathway given the shared 
and added cognitive component. In addition, we speculate that the specific regional 
location of WMH, in particular, damage to frontal areas of the brain may impact dual-
task performance. Previous functional neuroimaging studies have confirmed this 
association by demonstrating increased activation under dual-task conditions within 
prefrontal brain regions [35]. Further, different pathologies can result in different changes 
to the brain and activity making it difficult to draw generalizable conclusions. Future 
studies should aim to elucidate pathways of WMH impact on gait among healthy 
individuals as well as on the spectrum of neurodegeneration.  
In contrast to the effect on gait velocity, we did not report significant results for the 
associations between WMH and stride time variability. Although gait variability is 
posited to be more sensitive to fall risk when compared to other gait parameters, there is a 
paucity of studies investigating this association. To the best of our knowledge, only one 
prior study has assessed the relationship between WMH and stride time variability [3]. 
This prospective cohort study in non-demented elderly individuals reported a significant 
positive association between WMH and stride time variability (n = 431; β = 0.13, p < 
0.05) [3]. An alternative explanation can be related to lack of power due to our limited 
sample size of 59 older adults. Notwithstanding, other studies examining additional 
quantitative measures of gait variability have produced equivocal results (see Chapter 2) 
warranting further exploration of the literature [3, 36-38].  
Several studies have examined neuroimaging markers necessary for the maintenance of 
gait stability. A recent study by Annweiler and colleagues [39] reported associations 
between higher stride time variability and greater temporal volume, a proxy for temporal 
lobe atrophy including the hippocampus. This study aligns with other studies suggesting 
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that stride-to-stride fluctuations may be dependent on hippocampal involvement. A 
community-based sample of individuals aged 70 years and older, reported an inverse 
association between hippocampal metabolism and stride length variability [40]. Another 
study in a well-characterized community-dwelling sample reported a significant 
association between lower grey matter integrity in the hippocampus and step length 
variability [41]. Considered together, our results along with these studies support that gait 
variability, a proxy for the efficiency of higher-level motor control may also be supported 
by cortical grey matter.  
While understanding the effect of WMH contributing to decreased gait velocity is 
important in preventing and treating motor impairments, lifestyle strategies may also 
offer protective benefits in later life. Although our study did not demonstrate an overall 
moderation effect of physical activity on the association between WMH and gait velocity, 
we demonstrated that there was a threshold effect. That is, in our study the magnitude of 
the PASE score sufficient to modify the association was ≤ 127. Hence, our findings 
underscore the importance of physical activity having protective effects against WMH 
burden and gait, which is supported by the cognitive reserve hypothesis [42]. In addition, 
we speculate that the emergence of a threshold may be in regards to the physical activity 
scale used. Even though the PASE is a valid and reliable self-reported tool to assess 
physical activity, its precision may be limited compared to objective measures [20, 21].  
Cognitive reserve is a concept that has been proposed to account for individual 
differences in trajectories of cognitive decline [42]. Defined as the ability of the brain to 
optimize performance through recruitment of brain networks, cognitive reserve reflects 
the capacity of the brain to offset symptoms of dementia [42]. We speculate that physical 
activity is a neuroprotective strategy as it reduces the loss of brain mass and strengthens 
compensatory functions. In fact, there are numerous studies showing that physical 
exercise can reverse atrophy in certain areas of the brain that are vulnerable to the aging 
process and can also increase brain activation although there is a paucity of study 
examining motor reserve [43, 44].  
85 
 
Furthermore, our findings of low and moderate level of physical activity moderating the 
association between WMH and gait velocity provides additional support for physical 
activity as a neuroprotective strategy. Further, it is possible that the PASE may not be 
representative of the types of activities that have previously been demonstrated to elicit 
changes at a neural and behavioural level. For example, in this study the physical activity 
scale asked individuals to report the duration and frequency of engaging in leisure time 
and household activity. The items pertaining to household activity include; light or heavy 
housework, home repairs, lawn work, outdoor gardening and caring for another person. 
These items are also assigned a higher weight in comparison to leisure time activities, 
yielding a higher score. Further, the literature supports that physical activity in the form 
of aerobic exercise presents many benefits to older individuals [8, 9]. Thus, future studies 
should aim to use more objective measures of physical activity.  
An alternative approach to using more objective measurements of physical activity may 
be to test the efficacy to physical exercise in slowing the progression of WMH and the 
subsequent impact on gait. In such instances, WMH may be used as a surrogate marker in 
exercise intervention trials to assess intervention efficacy. To date, one randomized 
controlled trial has adopted this approach. In this study, researchers examined whether 
resistance-training twice weekly over 12 months in community-dwelling older women 
aged 65–75 reduced WMH progression, and whether WMH progression was associated 
with gait velocity [45]. Findings from this study suggest that resistance training slowed 
WMH progression and it was also associated with maintenance of gait velocity [45]. As a 
result, modifiable lifestyle strategies may represent an accessible alternative to 
pharmacological approaches to mitigate WMH burden in this population, however more 
randomized controlled trials are warranted to strengthen this evidence and to determine 
the most effective strategies.   
3.3.1 Limitations 
The cross-sectional nature of our study precludes us to infer causality. Studies that are 
longitudinal, either observational or interventional, may offer insights into a causal 
relationship. Our measure of physical activity was self-reported, which may present 
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issues related to participant bias. Additionally, even though we employed a quantitative 
approach to delineating WMH, this method was only capable of yielding a value 
pertaining to total WMH burden and could not infer whether white matter damage 
extended to areas of the normal-appearing white matter, or the exact location of affected 
pathways. Lastly, our sample size was relatively small, and may have contributed to the 
lack of significant findings especially on gait parameters of stride time variability.  
3.4 Conclusion        
In conclusion, our study demonstrated that WMH are associated with slowing gait 
velocity, and that this association is modified by physical activity, even though this 
association is threshold dependent. This suggests that the effects of WMH burden may be 
attenuated by modifiable lifestyle intervention strategies such as physical exercise. 
Further studies aimed at determining whether physical exercise has an impact on WMH 
burden and gait are needed to confirm this association.      
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Appendices 
Appendix A: Search Strategy 
CONCEPT EMBASE MEDLINE (OVID) PUBMED KEYWORDS 
WHITE 
MATTER 
CHANGES 
Leukoaraiosis/ OR 
White matter lesion/ 
OR 
Leukoencephalopathy/ 
OR Diffusion Tensor 
Imaging/ 
 
Leukoaraiosis/ OR 
Leukoencephalopathies/ 
OR Diffusion Tensor 
Imaging/ 
 
“Leukoaraiosis” [MeSH] 
OR 
“Leukoencephalopathies” 
[MeSH] OR “Diffusion 
Tensor Imaging” 
Leukoaraios* OR 
Leucoaraios* OR White 
matter lesion* OR White 
matter hyperintensit* OR 
white matter change* OR 
White matter disease* OR 
Leukoencephalopath* OR 
White matter integrity OR 
White matter 
microstructure or 
Diffusion Tensor Imaging 
MOBILITY Physical mobility/ OR 
Gait/ OR Balance 
impairment/ OR exp 
Falling/ OR Fracture/ 
Mobility Limitation/ OR 
Gait/ OR Postural 
balance/ OR Accidental 
falls/ OR Fractures, 
Bone/  
“Mobility Limitation” 
[MeSH] OR “Gait” 
[MeSH] OR “Postural 
Balance” [MeSH] OR 
“Accidental Falls” 
[MeSH] OR “Fractures, 
Bone” [MeSH] 
Mobility OR Mobility 
Limitation* OR Gait OR 
Balance OR Postural 
Instability OR Postural 
Sway OR Fracture* OR 
Fall*  
 
OLDER 
ADULTS 
Aged/ OR Geriatrics/  Aged/ OR “Aged, 80 and 
over”/ 
“Aged” [MeSH] OR 
“Aged, 80 and over” 
[MeSH] 
Older adult* OR Elderly 
OR Geriatric* 
RECORDS 
FOUND 
572 154 588 1314 
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Appendix C: Conceptual Overview of the Lesion Segmentation Algorithm 
 
The flow diagram of the lesion segmentation algorithm is shown. Preprocessing with the 
standard software of SPM8 and VBM8 is illustrated in the gray box. At first, the 
individual native T1 image is used to generate a partial volume estimate (PVE) label. To 
94 
 
this end, some normalization is necessary. To surpass smoothing of the individual images 
by warping, the algorithm operates in native space exclusively. Thus, preprocessing 
includes the coregistration of FLAIR images to T1 images, PVE label estimation but 
output in native space, as well as inverse warping of the white matter (WM) tissue 
probability map ( /react-text TPMWM react-text: 2537 ) to native space by the use of the 
inverse deformation matrix derived from PVE label estimation. Next, FLAIR intensity 
distribution is calculated for each of the three tissue classes to detect FLAIR-hyperintense 
outliers which are further weighed according to their spatial probability of being WM 
resulting in belief maps ( /react-text BWM react-text: 2540 , /react-text BCSF react-text: 
2543 , /react-text BGM react-text: 2546 ). Now, the three lesion belief maps are summed 
up ( /react-text B react-text: 2548 ). The binary version (threshold /react-text κ react-text: 
2550   /react-text react-text: 2551 = /react-text react-text: 2552   /react-text react-text: 
2553 0.3) of the GM lesion belief map is used as initial lesion map ( /react-text Linit 
react-text: 2557 ). Finally, the lesion growth model expands the /react-text Linit react-
text: 2561 , a conservative assumption for lesions, toward the lesion belief map ( /react-
text B react-text: 2563 ), a liberal assumption for lesions (see text for details). 
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Appendix D: Outcome Distributions 
White matter hyperintensities: 
Untransformed Distribution Transformed Distribution 
White matter hyperintensities volume: 
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Physical activity: 
Untransformed Distribution Transformed Distribution 
Physical Activity Scale in the Elderly: 
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Gait characteristics under single-task conditions: 
Untransformed Distribution Transformed Distribution 
Gait velocity (units): 
 
 
Stride time variability (CoV): 
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Gait characteristics under dual-task counting gait condition: 
Untransformed Distribution Transformed Distribution 
Gait velocity (units): 
 
 
Stride time variability (CoV): 
 
 
 
Dual-task cost gait velocity:  
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Dual-task cost stride time variability 
(CoV): 
 
Cannot be transformed. 
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Gait characteristics under dual-task serial seven gait condition: 
Untransformed Distribution Transformed Distribution 
Gait velocity (units): 
 
 
Stride time variability (CoV): 
 
 
 
Dual-task cost gait velocity: 
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Dual-task cost stride time variability 
(CoV): 
 
Cannot be transformed. 
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Gait characteristics under dual-task naming animals gait condition: 
Untransformed Distribution Transformed Distribution 
Gait velocity (units): 
 
 
Stride time variability (CoV): 
 
 
 
Dual-task cost gait velocity: 
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Dual-task cost stride time variability 
(CoV): 
 
Cannot be transformed. 
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